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 Spray congealing has been used over 5 decades to produce particulates 
by the food and pharmaceutical industries. The latter have used this 
technology to develop specialised drug delivery systems with meltable 
materials. Various types of polymeric admixtures and additives may be 
incorporated into the melt carrier matrix to modify the final product properties, 
in particular, the drug release.  
In this study, various grades of polyethylene glycol (PEG) and types of 
additives commonly used in formulating modified release dosage forms were 
screened for their suitability as a meltable matrix and matrix modifier, 
respectively, for spray congealing. The impact of grade and concentration of 
selected additives on the properties of the molten mixtures, metronidazole 
(MNZ), PEG matrix and spray congealed microparticles were investigated. 
Suitable formulations were then selected for the production of spray congealed 
microparticles, which were then compressed into tablets as the final dosage 
form.  
The grade of PEG used was found to affect the crystallinity and 
thermodynamic stability of MNZ. Viscosity of the molten mixture had also 
played an important role in affecting the crystallinity of MNZ. Screening of 
the additives showed that hydroxypropyl methylcellulose (HPMC) was the 
appropriate matrix modifier as it dispersed uniformly in molten PEG and the 
molten mixture had low viscosity, which is amendable to spray congealing. 
An understanding of the rheological behaviour of polymer melt 
suspensions is crucial in pharmaceutical manufacturing, especially for spray 
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congealing. Rheological studies showed that the amount and particle size of 
HPMC, besides temperature, affected the viscosity of PEG melt suspensions. 
Using principal component analysis, the ternary melt suspensions consisting of 
PEG, MNZ and HPMC of different grades were classified into three clusters, 
namely low, moderate and high according to their final melt suspension 
viscosities. The classification of formulation viscosities allows the selection of 
an appropriate grade and concentration of HPMC to achieve the desired spray 
viscosity for spray congealing. Formulations in the low viscosity cluster were 
found to be the most easily sprayable.  
The impact of various grades and concentrations of HPMC on the 
properties of the PEG matrix and MNZ was subsequently studied using the 
melt solidification method and by spray congealing. The addition of HPMC 
decreased the size of the microparticles obtained, indicating a decrease in 
mechanical strength of the PEG matrix. The reduction in MNZ crystallinity 
was due to the presence of HPMC and not the viscosity of the molten mixture. 
HPMC was successfully incorporated into spray congealed PEG-MNZ 
microparticles. Spherical and free-flowing microparticles with good yield and 
high encapsulation efficiency of MNZ were obtained. The HPMC 
concentration influenced the viscosity of the molten mixture and size of the 
resultant microparticles. Particle size of HPMC exerted a significant effect on 
MNZ crystallinity. The amorphous and molecularly dispersed MNZ in the 
microparticles was stable thermodynamically during storage.  
The swelling extent of microparticles was influenced by the grade, 
particle size and number of HPMC particles employed. Drug dissolution was 
influenced by matrix erosion of the microparticles. A fast rate of erosion 
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would result in increased drug dissolution and vice versa. Formation of the 
barrier and the grade of HPMC used affected the rate of erosion of 
microparticles and modified the release of rifampicin. Further modification of 
drug release of spray congealed PEG-HPMC microparticles could be achieved 
with the incorporation of other additives, such as dicalcium phosphate. 
Formulation and operation parameters of the rotary tablet press for selected 
spray congealed microparticles were optimised and tablets with suitable 
hardness and disintegration time were successfully produced.  
 This research study provided insights into the impact of PEG and 
HPMC as a drug carrier in the formulation of spray congealed matrix for 
modulating drug release. The work also had contributed to a deeper 
understanding of the effect of various grades and concentrations of HPMC on 
the rheological properties of the molten mixtures and properties of PEG 
matrix, MNZ and spray congealed microparticles, such as drug crystallinity 
and matrix swellability.  
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A. Spray congealing 
1. The process of spray congealing 
Spray congealing, also known as prilling, spray chilling or spray 
cooling, is a process in which a hot molten mixture is atomised into a cooled 
chamber where the molten droplets congeal to form solid particles. The molten 
mixture consists of one or more active principles which may be melted, 
dispersed or dissolved in a molten matrix material. The active principle, 
matrix material and spray congealed particles are also referred to as drug/core, 
carrier and microparticles respectively. Matrix material should exist as a solid 
at ambient temperature and have a suitable melting point or range, typically in 
the range of 50 to 100 °C. The transformation of molten droplets from liquid 
to solid is usually achieved by the removal of heat energy from the droplets in 
a cooled chamber. Congealing can also be accomplished by spraying the 
molten mixture into liquid nitrogen, chilled organic solvent, desolvating liquid 
or sorptive particles.  
Spray congealing may also be considered as a method of 
microencapsulation, where the active principle is embedded in the spray 
congealed microparticle (Ghebre-Sellassie, 1989). If the active principle is 
insoluble in the molten matrix, it will either be embedded at the core or 
distributed in the matrix of the microparticle (Figure 1). If the active principle 
dissolves in the molten matrix, it may exist as molecular dispersion in the 
matrix on cooling. This technology has been used as the primary means of 
microencapsulation for a wide range of pharmaceuticals, foods and flavours 
(Deasy,  1984; Gibbs et  al . ,  1999; Lee, 1981; Tobío et  al . ,  1999) . 
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It can be employed to produce specialised drug delivery systems (Thies, 
1996). With the proper selection of matrix material, the encapsulation process 
can enhance stability (Bakan, 1973; Bakan and Anderson, 1976; Lin et al., 
1995; Maschke et al., 2007; Schwendeman et al., 1996; Sinha and Trehan, 
2003; Taguchi et al., 1992; Wanasundara and Shahidi, 1995), increase 
flowability (Lee, 1981), mask taste (Deasy, 1984; Yajima et al., 2002; Yajima 
et al., 2003; Yajima et al., 1996; Yajima et al., 1999), reduce gastrointestinal 
irritation (Frenkel et al., 1968) and/or alter release properties (Bodmer et al., 
1992; Deasy, 1984; Park et al., 2004; Passerini et al., 2003) of the active 
principles. Over the last few decades, researchers had explored the application 
of spray congealing to various matrix materials and active principles to 
produce particles of different size, shape and solubility (Appendix 1). 
 
 
Figure 1. Distribution of drug within spray congealed particle. 
 
A schematic diagram of the spray congealer and the process overview 
are shown in Figures 2 and 3 respectively. The matrix material is first heated 
to a temperature of approximately 10-20 °C above its melting point and the 
active principle(s) is/are then incorporated into the molten matrix material 
with constant stirring to obtain a uniform mixture. The molten mixture is then 




Figure 2. Schematic diagram of the spray congealer. 
 
 















fine spray in a chamber. The molten droplets tend to assume a spherical shape 
due to the effects of surface tension and state of air suspension. They are 
cooled to temperatures below the melting point of the matrix material by cool 
air. Heat is removed from the molten droplets, resulting in their congealation 
to form solid spherical particles. The larger particles are collected in a vessel 
below the cooling chamber while very fine particles are conveyed with the 
exhausting air flow to a cyclone where they are separated from the air stream 
and collected in another collection vessel. Alternatively, all the spray 
congealed particles are conveyed to the cyclone. The residence time for 
sprayed droplets in the cooling chamber is usually short, ranging from several 
seconds to a few minutes. Typically, the spray congealed product consists of 
dense round spheres of less than 1 mm in diameter, which can adeptly be 
called microparticles, micropellets or microspheres. 
 
2. Advantages and disadvantages 
Both spray drying and spray congealing involve the atomisation of 
liquid feed to eventually produce solid particles. In spray drying, a solution or 
suspension containing the active principle and/or excipient is sprayed into a 
stream of hot air. The particles produced using spray drying technique 
generally have irregular geometry and porous surfaces due to the evaporation 
of solvent, typically water or ethanol (Ghebre-Sellassie and Knoch, 1995). 
Thus, any coating attempts by spray drying may be adequate for taste masking 
and other purposes but not for controlled drug release (Deasy, 1984). 
Conversely, particles produced using spray congealing are generally dense, 
spherical and smooth surfaced as there are no internal evaporative effects on 
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the spray congealed products (Hincal and Kaş, 1994). The properties of spray 
congealed particles make them highly suitable for secondary processing such 
as tabletting and capsule filling. Several researchers had also reported that 
spray congealed particles possessed desirable sizes and shapes, high drug 
encapsulation efficiency and exhibited acceptable syringeability/injectability 
(Deng et al., 2003; Li et al., 2005). Another advantage of spray congealing 
technique is that microparticles can be prepared without water or organic 
solvents (Reithmeier et al., 2001; Rodriguez et al., 2004). This makes spray 
congealing an environmentally friendly process that is attractive for the 
processing of moisture sensitive drugs. It also eliminates the drying step and 
the risk and toxicity associated with organic solvents (Witschi and Doelker, 
1997). The microparticles can also be collected and processed immediately 
after production, without the need for additional processing steps (Janssens 
and Van den Mooter, 2009).  
A major disadvantage of spray congealing is that the active principles 
and additives included must be stable at the temperature required to melt and 
maintain the matrix material in molten form (Turton and Cheng, 2006). This 
limits the choice of matrix material for thermolabile drugs such as 
erythromycin, acyclovir and isotretinoin. Furthermore, the choice of matrix 
material is also constrained by the melting temperature which may be too 
high. Examples of materials which have very high melting temperature and 
unsuitable for use are mannitol (m.p. 166 to 168 °C) and sucrose (m.p. 160 to 
186 °C). Some matrix materials such as glycerides and carnauba wax may 
undergo physical changes during the process, which can affect the stability 
and dissolution of the drug (Eldem et al., 1991; Emås and Nyqvist, 2000). The 
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process of spray congealing is not favourable for highly viscous molten 
mixtures as it may cause clogging of the feed tube or the atomizer. The active 
principle must also be compatible with the matrix material and does not 
sediment easily in the feed tube prior to atomisation. Surfactants or dispersing 
agents may be used to overcome the latter problem. 
 
3. Influence of matrix materials 
For spray congealing, the matrix material must be a molten liquid at an 
elevated temperature and when atomised, forms fine droplets that congeal in 
the cooled chamber (Deasy, 1984). When assessing the suitability of a matrix 
material for spray congealing, two important properties must be considered, 
namely the melting temperature and heat stability of the matrix material. The 
matrix material should melt without any decomposition when heated to the 
desired temperature above its melting point and should exist as a hard solid at 
ambient temperature. Sufficient cooling capacity is difficult to achieve for 
matrix material with a very low melting point. On the other hand, matrix 
material with a high melting point requires a high operating temperature for 
the liquid delivery and atomisation system. The matrix materials commonly 
used for spray congealing for pharmaceutical uses have melting points in the 
range of 50-80 °C. The properties of the spray congealed particles are 
dependent on properties such as the solubility and hydrophobicity of the 
matrix material (Deasy, 1984). Therefore, the selection of matrix materials is 
normally based on the afore-mentioned physical properties and ability of the 
chosen/selected matrix material to produce the desired end product. 
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Different types of waxes such as white wax, carnauba wax, 
hydrogenated castor oil, cetyl alcohol, glyceryl monostearate and glyceryl 
tristearate were employed to produce sulfaethylthiadiazole-loaded 
microparticles (Cusimano and Becker, 1968). The type of wax used was found 
to affect the size, porosity and specific surface area of the microparticles and 
their drug release characteristics. Formulations containing white wax and 
glyceryl tristearate gave the smallest microparticle size while cetyl alcohol and 
hydrogenated castor oil had the largest. Furthermore, carnauba wax produced 
microparticles that had the lowest porosity and specific surface area. Increased 
wax viscosity decreased the size of microparticles produced. Drug release 
from the microparticles was dependent on the physical properties of the 
microparticles as well as the composition of the wax and dissolution medium. 
Microparticles with a higher specific surface area showed higher dissolution 
rates. Waxes are composed of different fatty acids and fatty alcohols. 
Microparticles formulated with glyceryl tristearate were found to have lower 
dissolution rate as the composition of fatty acid esters are less susceptible to 
alkaline hydrolysis. A more alkaline dissolution medium can emulsify, 
disintegrate and solubilise particles more readily. Higher recovery of fenbufen 
was obtained from stearic acid microparticles compared to carnauba wax 
microparticles (Rodriguez et al., 1999). In addition, stearic acid microparticles 
had a higher rate of drug release than carnauba wax microparticles due to the 
lower hydrophobicity and faster erodibility of stearic acid. Spray congealed 
carnauba wax was also found to reduce photodegradation of the sunscreen 
agent, avobenzone, making spray congealing a useful approach to protect 
photosensitive drugs (Albertini et al., 2009a). 
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The effect of formulation viscosity on the characteristics of spray 
congealed particles had been studied by several researchers but the findings 
were not always in agreement. Albertini et al. (2008) reported that high 
viscosities resulted in larger particles with a two fluid atomiser. However, 
Scott et al. (1964) found that viscosity had an inverse effect on the size of 
particles produced with a rotary atomiser and changes in viscosity within a 
certain range had negligible effects. Furthermore, other researchers also 
demonstrated that increased feed viscosity resulted in smaller particles when 
produced using an ultrasonic atomiser (Passerini et al., 2002). It had also been 
reported that a highly viscous feed had caused blockage of the atomiser 
nozzle, necessitating termination of the process (Yajima et al., 1996). 
Enhanced dissolution of indomethacin was achieved by encapsulating 
the drug in a water soluble polyethylene glycol matrix (Fini et al., 2002). 
Hydrophilic stearoyl macrogol glycerides were used to improve the solubility 
of poorly water soluble drugs such as carbamazepine, diclofenac, piroxicam 
and praziquantel (Cavallari et al., 2005; Passerini et al., 2006; Passerini et al., 
2002; Qi et al., 2010). Significant increase in drug dissolution rate from the 
microparticles was obtained when compared with drug powder or physical 
mixture of drug and matrix material. On the other hand, sustained release 
could be achieved by using lipophilic matrix materials. The use of 
hydrogenated soybean oil was found to sustain the release of aspirin (Guo et 
al., 2005), while microcrystalline wax and stearyl alcohol were able to control 
the release of verapamil (Passerini et al., 2003). Salbutamol sulphate prepared 
with glyceryl behenate achieved extended release properties which was not 
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seen when tristearin or stearic acid was used (Albertini et al., 2013). This was 
attributed to the affinity between drug and lipid material.  
Taste masking is often required for pharmaceutical oral dosage forms 
because a large number of drugs have bitter or unpleasant taste. Spray 
congealing is a useful technique for taste masking. Yajima et al. (2002; 2003; 
1996; 1999) had undertaken extensive investigative work to mask the taste of 
clarithromycin. Microparticles of glyceryl monostearate and aminoalkyl 
methacrylate copolymer E containing clarithromycin were prepared. The 
optimal formulation enabled very slow drug release in the mouth but rapid 
drug release in the stomach. The microparticles were further processed into a 
dry syrup formulation. The palatability and taste of the dry syrup were 
significantly improved after encapsulation of clarithromycin by spray 
congealing. In a later study, the release of clarithromycin was determined 
using a mini-column packed with the dry syrup. The release results showed a 
good correlation with the sensory test results. In another study, the bitterness 
of a commercial clarithromycin dry syrup product was determined using an 
artificial multi-channel taste sensor (Uchida et al., 2003). The bitter taste was 
almost completely masked by the aminoalkyl methacrylate polymer matrix. 
Improved immunogenicity of tetanus toxoid delivery system could be 
achieved by spray congealing and solvent evaporation encapsulation 
techniques (Schwendeman et al., 1998; Tobío et al., 1999). Tetanus toxoid was 
incorporated into the gelatin/poloxamer matrix mixture and spray congealed to 
form microparticles. The microparticles were further coated with poly(lactic-
co-glycolic acid). The activity of the vaccine was stabilised in the core and 
release was brought about by erosion of the polymer coat. The release of 
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tetanus toxoid from this delivery system was slow but continuous and induced 
a high and long lasting immune response. 
 
4. Influence of active pharmaceutical ingredients (APIs) 
Besides drugs/active principles, encapsulation of proteins, vaccines 
and other solid particles has been attempted with a variety of matrices using 
the spray congealing technique. The core material to be encapsulated may be 
suspended, melted or dissolved in the molten matrix. Drugs possessing certain 
properties such as heat stability, small particle size and regular particle shape 
are more amenable to spray congealing. A heat labile drug should not be spray 
congealed due to the potentially detrimental effects of prolonged heating in the 
molten matrix feed.  
The solid drug particles were shown to affect the properties of 
microparticles. Drug-loaded microparticles produced using either an ultrasonic 
atomiser or rotary atomiser were found to be smaller in size than the 
corresponding drug-free microparticles (Cavallari et al., 2005; Deng et al., 
2003; Passerini et al., 2002; Rodriguez et al., 1999). The amount of 
microparticles obtained per unit time was found to decrease with increasing 
drug load. The atomisation process was depressed by the incorporation of drug 
in the matrix material and a longer sonication time was required to atomise the 
same amount of feed material. Consequently, the feed material was exposed to 
a greater amount of energy during atomisation, resulting in smaller 
microparticles produced. The drug encapsulation efficiency decreased with 
decreasing particle size of the microparticles. However, in another study, the 
size of microparticles was found to increase with increasing concentration of 
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insulin when a pressure atomiser was used (Maschke et al., 2007). In addition, 
microparticles prepared using a two fluid atomiser exhibited larger size with 
higher loading of bovine serum albumin (Di Sabatino et al., 2012).  
Drug release was dependent on the solubility of drug and lipophilicity 
of matrix material (Passerini et al., 2003; Rodriguez et al., 1999). Drugs with 
higher water solubility were reported to have higher rates of release from the 
same type of matrix material. Amorphous drug was released at a higher rate 
than crystalline drug (Savolainen et al., 2002). Encapsulation of praziquantel 
in a hydrophilic stearyl macrogol glyceride matrix increased its dissolution 
rate (Passerini et al., 2006). Drug release was significantly enhanced at drug 
load of 5 and 10 %, w/w of praziquantel. Further increase in drug load to 20 
and 30 %, w/w of praziquantel resulted in reduced release rate from the 
microparticles. The solubility of praziquantel in the matrix was the major 
determinant for drug release. At a low concentration, the drug could be 
dissolved in the molten matrix and existed as molecular dispersion upon 
solidification of the matrix. However, at a high drug load, the solubility limit 
was exceeded and a large proportion of the drug particles remained in their 
original crystalline form in the matrix. The reduced drug release rate was 
attributed to the presence of these crystalline forms of drug particles. Qi et al. 
(2010) found that the drug release of smaller microparticles (< 63 µm) was not 
affected by the drug load but larger microparticles showed lower release rates 
at high drug loads. Ageing effect of the microparticles also led to a higher 
release rate of these larger microparticles. However, Deng et al. (2003) found 
that a higher drug load enhanced drug release from microparticles. 
Microparticles comprising more than 50 %, w/w of bupivacaine exhibited 
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marked initial burst release while microparticles with lower bupivacaine load 
showed moderate initial burst release. In another study, it was reported that the 
shape, size and size distribution of encapsulated proteins affected their release 
kinetics from triglyceride-based microparticles (Zaky et al., 2010). Larger 
protein particles of elongated shape led to faster release. This was attributed to 
the larger pores and channels created after protein release, allowing more 
medium penetration into the microparticle. On the other hand, the smaller 
protein particles which were more uniformly distributed throughout the 
microparticle created more tortuous networks upon release, hindering 
penetration of medium and slowing the protein release rate.  
Some of the effects of encapsulated active principles on the properties 
of the microparticles are summarised in Table 1. Microparticles produced with 
carnauba wax, hydrogenated castor oil, glyceryl palmitostearate, glyceryl 
behenate, glyceryl tristearin, tristearin or microcrystalline wax had smooth 
surfaces whereas those produced with stearic acid or stearyl alcohol had 
rougher surfaces (Passerini et al., 2003; Rodriguez et al., 1999; Savolainen et 
al., 2002). The addition of drug increased the surface roughness of 
microparticles due to the presence of drug particles on the surfaces (Al-Kassas 
et al., 2009; Rodriguez et al., 1999) or recrystallisation of the dissolved drug 
on the surfaces (Cavallari et al., 2005). More imperfections were found on 
microparticles with encapsulated crystals that were larger and less 
symmetrical. The surface of microparticles containing the less stable 
crystalline drug forms was smoother than that of microparticles containing the 




Table 1. Effects of various encapsulated active principles on the properties of 
the microparticles. 
Active principle Matrix Effects 




Stabilisation of the metastable 




obtained when drug was 
incorporated Diclofenac Stearyl macrogol 
glyceride 
Lidocaine Glyceryl behenate Higher drug load resulted in 
irregular microparticles and 
filament formation 
Insulin Glycerol tripalmitate Surface morphology of 
microparticles improved, with 
higher concentrations of insulin 





No improvement in the surface 
property of microparticles 
 
5. Influence of additives 
Various additives have been added to alter the physicochemical 
properties of spray congealed microparticles. The incorporation of sorbitan 
monooleate had no effect on the size of wax microparticles but it caused 
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extensive agglomeration and impaired their flow properties (John and Becker, 
1968). The concentration of sorbitan monooleate exerted different effects on 
drug release from the microparticles in different dissolution media. In 
hydrochloric acid solution (pH 1.1), microparticles containing sorbitan 
monooleate at concentrations of 1 and 4 %, w/w showed increased drug 
release. However, at 10 %, w/w sorbitan monooleate, marked decrease in drug 
release rate from the microparticles was observed. Sorbitan monooleate could 
promote wetting of the microparticles by the dissolution medium, which 
consequently increased the rate of drug release from the microparticles. 
However, microparticles containing 10 %, w/w sorbitan monooleate were 
tacky and easily formed agglomerates. Hence, the total surface area exposed to 
the dissolution medium was reduced. In addition, it was proposed that a high 
concentration of sorbitan monooleate had resulted in the formation of an 
emulsion which entrapped the eluant and retarded the diffusion of the 
dissolved drug. Interestingly, in alkaline pancreatin solution, sorbitan 
monooleate enhanced drug release regardless of its concentration. This was 
probably due to disintegration of the microparticles by the action of pancreatin 
and the alkalinity of sodium bicarbonate used in the solution. In another study, 
the microparticles were compressed into tablets and their drug release rates 
were investigated (Hamid and Becker, 1970). Drug release was generally 
slower from the compressed microparticles than uncompressed microparticles 
in both acidic and alkaline media. Increasing the concentration of surfactant 
within microparticles decreased the drug release rate from the compressed 
microparticles in acidic medium. It was explained that higher concentration of 
sorbitan monooleate caused more cohesiveness of the particles. Thus, the 
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surface area of microparticles exposed to the dissolution medium was reduced, 
resulting in slower drug release. In addition, the force employed during 
compression could reduce the particle porosity and further hindered drug 
release. On the other hand, drug release from the uncompressed microparticles 
in alkaline medium increased with the concentration of sorbitan monooleate. 
Increased release of drug was due to the reduced surface tension brought about 
by sorbitan monooleate in the dissolution medium. 
The effect of sorbitan monostearate on the properties of microparticles 
was also investigated in another study (Cusimano and Becker, 1968). Sorbitan 
monostearate had no significant effect on the size of microparticles but 
affected the drug release profiles. Drug release was dependent not only on 
sorbitan monostearate concentration but also on the type of wax matrix. Drug 
release from hydrophobic wax microparticles increased as the concentration of 
sorbitan monostearate increased. Sorbitan monostearate not only improved the 
wetting of microparticles, it also made the microparticles more porous as it 
dissolved into the dissolution medium. Thus, drug release was enhanced. Drug 
release rate from hydrophilic wax microparticles decreased as the 
concentration of sorbitan monostearate increased. Cetyl alcohol and glyceryl 
monostearate were capable of being hydrated in aqueous medium and their 
hydration capacity was reduced by sorbitan monostearate. As a result, the drug 
release process was impeded.  
In addition to drug release, surfactants were found to affect other 
properties of microparticles. It was reported that lecithin affected the phase 
transformation of the lipid matrix (Eldem et al., 1991). Lecithin was 
incorporated into the crystalline lattice and prevented the metastable form 
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from converting into the stable form during the spray congealing process and 
during storage at or below ambient temperature. Complete transformation to 
stable form was achieved for microparticles with and without lecithin by 
storage at elevated temperatures. Lecithin smoothened the surface of 
cetostearyl alcohol microparticles (Albertini et al., 2008) but it caused surface 
irregularities in microcrystalline wax microparticles (Passerini et al., 2003). 
Surfactants such as poloxamer 188, sorbitan monooleate and polyoxyethylene 
sorbitan monooleate were found to increase the particle size but had no effect 
on the size span of triglyceride microparticles produced (McCarron et al., 
2008).  
Besides surfactants, inert excipients also affected the properties of 
spray congealed microparticles. Addition of low molecular weight 
polyethylene to carnauba wax, hydrogenated castor oil or synthetic wax-like 
ester matrix resulted in larger microparticles (Raghunathan and Becker, 1968). 
The increase in size of microparticles was linearly related to the concentration 
of low molecular weight polyethylene added. This trend was not seen for 
ethylcellulose and glyceryl ester of hydrogenated rosin. Differences in the 
effect of excipient on drug release were also observed. Drug release appeared 
to follow second order kinetics; a function of the effective surface area of the 
drug particles and amount of drug remaining to be dissolved. The 
incorporation of low molecular weight polyethylene decreased the drug 
release rate from hydrogenated castor oil and synthetic wax-like ester 
matrices. The addition of glyceryl ester of hydrogenated rosin hindered drug 
release from hydrogenated castor oil and carnauba wax matrices. However, the 
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incorporation of ethylcellulose enhanced the release of drug from carnauba 
wax and synthetic wax-like ester matrices. 
Calcium carbonate and glyceryl monostearate were found to affect the 
drug release from lipid-lipase microparticles (Javaid et al., 1971). Drug release 
rate from lipid microparticles containing lipase was increased with higher 
calcium carbonate concentration. Low concentration of glyceryl monostearate 
enhanced the drug release from lipid microparticles with lipase but high 
concentration impeded the drug release. Without lipase, calcium carbonate and 
glyceryl monostearate had no effect on the drug release profile from the lipid 
microparticles.  
Lipid microparticles containing theophylline were produced using an 
ultrasound atomiser. Colloidal silicon dioxide, such as Aerosil 90 and Aerosil 
200, was added into the molten matrix to retard the sedimentation of the drug 
particles. It was found to affect various properties of the microparticles 
(Albertini et al., 2004). The size of microparticles was decreased but their 
surface roughness was unaffected. The drug release depended on the 
concentration and specific surface area of the colloidal silicon dioxide. 
Controlled drug release could be achieved by using a high concentration of 
colloidal silicon dioxide of higher specific surface area, such as 200 or 300 
m
2
/g. When hydrophobic silicon dioxide, such as Aerosil R812 or Aerosil 
R972 was used, it enabled uniform drug loading and increased microparticle 
size, but produced rougher microparticle surfaces and decreased the drug 
release (Albertini et al., 2008). 
Mucoadhesives, such as chitosan, sodium carboxymethylcellulose and 
poloxamers, have also been used to develop microparticles for vaginal 
19 
 
delivery of econazole nitrate (Albertini et al., 2009b). The poloxamers were 
better at improving the solubility and adhesion of the microparticles to the 
mucosal tissue. An increase in the poloxamer concentration in the 
microparticles was found to enhance drug release (Lo et al., 2009). 
 
B. Solid dispersions 
1. Significance of solid dispersions 
Spray congealing is commonly employed to produce solid dispersions. 
The latter, which consist of dispersions containing one or more active 
principles in inert matrix materials in the solid state, may also be prepared by 
the melting (fusion), solvent or melting-solvent methods (Chiou and 
Riegelman, 1971). The drug can be dispersed molecularly, as amorphous 
particles (clusters) or as a dispersion of crystalline particles (Figure 4).  
 
 
Figure 4. Schematic representation of three modes of incorporation of the 
active principle in a solid dispersion. 
 
It was observed that the cooling rate could affect the crystallinity of the 
drug and/or matrix material, which in turn influenced the properties of the 









and Wells, 1997; Sjokvist Saers et al., 1993). Spray congealed microparticles 
can be classified as solid solutions, solid suspensions or a mixture of both 
(Vasconcelos et al., 2007). In solid solution, the drug and matrix material 
exhibit homogeneous molecular interaction and are totally miscible with each 
other. The crystalline drug is dissolved, creating an amorphous or molecularly 
dispersed product (Van den Mooter et al., 2006; van Drooge et al., 2006). A 
solid suspension is produced when the drug has limited matrix solubility or an 
extremely high melting point. Molecularly, the resultant dispersion does not 
have a homogeneous structure but is composed of two phases (Vasconcelos et 
al., 2007). Small drug particles in the nano-meter range when dispersed in 
polymeric carriers may produce an amorphous product (van Drooge et al., 
2006). In most spray congealed microparticles, part of the drug added is 
dissolved in the matrix carrier while the balance is suspended, resulting in a 
heterogeneous dispersion with mixed properties of solid solutions and solid 
suspensions. In solid dispersions, the drug release profile is dictated 
considerably by carrier dissolution properties (Vasconcelos et al., 2007). 
 Solid dispersion has been shown to be a promising strategy in 
improving the oral bioavailability of drugs. Examples reported include the use 
of poloxamer as a matrix to increase the dissolution of ibuprofen (Newa et al., 
2007; Patil et al., 2011). A significant increase in drug release can be achieved 
through solid dispersions because of the reduced drug particle size, improved 
wettability, higher porosity and the amorphous state of the drug (Vasconcelos 
et al., 2007). Several commercially available solid dispersion preparations, 
such as griseofulvin with polyethylene glycol (PEG) 8000 (Gris-PEG®) and 
itraconazole with PEG 20000 and hydroxypropyl methylcellulose 
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(Sporanox®), have been shown to increase the rate and extent of dissolution 
of these drugs (Kumar and Vandana, 2012; Singh et al., 2011). 
 
2. Crystallisation and amorphism 
The physical state of drug, amorphous or crystalline, is an important 
consideration in the development of pharmaceutical drug products. Varying 
degrees of drug amorphism can be generated through pharmaceutical 
processes such as milling, wet granulation, drying and compaction (Zhang and 
Zhou, 2009). The amorphous content of the drug can determine the properties 
of the resultant product. For example, it can confer advantages such as 
improvement in dissolution for a poorly water soluble drug and enhance 
bioavailability (Byrn et al., 1995; Haleblian, 1975). Many potential drug 
candidates are hydrophobic in nature and therefore, the process of amorphism 
of drugs is a powerful approach in mitigating the poor administration, 
distribution, metabolism and elimination (ADME) profiles of these drugs.  
While amorphism of drugs can be induced during product 
development, it is also important to inhibit crystallisation of the amorphous 
drug upon dissolution. The higher dissolution rate and apparent solubility of 
the amorphous drug may cause supersaturation during in vivo dissolution, 
leading to recrystallisation/precipitation in the gastrointestinal tract and hence, 
compromising the bioavailability of the drug (Zhang and Zhou, 2009). This is 
especially evident for Biopharmaceutics Classification System (BCS) class IV 
substances. Any improvement in dissolution can be masked as the low 
permeation through the gut wall allows time for recrystallisation of the poorly 
soluble drug to occur (Fahr and Liu, 2007).  
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 To understand the underlying mechanism of crystallisation inhibition, 
the process of nucleation and crystal growth will be discussed. Nucleation 
occurs when the activation energy of nucleation in a supersaturated solution is 
surmounted (Janssens and Van den Mooter, 2009). Surfaces and particles will 
decrease the activation energy and therefore facilitate the nucleation process. 
The nucleation rate increases with increasing degree of supersaturation and 
with a decrease in the interfacial energy between the nucleus and solvent. The 
former can be influenced by the presence of additives while the latter by the 
presence of surfactants. Crystal growth comprises two steps: (1) diffusion of 
molecules from the bulk of the solution towards the crystal interface, and (2) 
integration of the molecules into the crystal lattice. The nucleation process and 
crystal growth can be delayed by drug–polymer interactions, by altering the 
viscosity of the solution and by adsorption of the polymer on the nucleus or 
the growing crystal, thereby inhibiting drug crystallisation (Raghavan et al., 
2003; Simonelli et al., 1970; Terayama et al., 2004; Zhang and Zhou, 2009).  
One study has shown that hydroxypropyl methylcellulose (HPMC) is 
able to induce the amorphism of drugs (Katzhendler et al., 1998). It was found 
that HPMC could inhibit the crystallisation of amorphous drugs such as 
albendazole, by reducing the nucleation rate (Kohri et al., 1999). It also had 
the ability to stabilize the amorphous drug. It was speculated that HPMC had 
affected the nucleation kinetics by increasing the kinetic barrier to nucleation. 
The effect seen was proportional to the concentration of HPMC (Konno and 





3. Screening of formulations using melting method  
Preliminary screening of potential matrix materials and additives is 
important to select the appropriate excipients for the intended purpose. 
Performing spray congealing of all potential formulations would be energy 
and time-consuming. A more effective approach is to pre-screen and only 
select good potential formulations based on the required properties before 
performing spray congealing. One of the methods that can be used to screen 
potential formulations is by the melting method. An important advantage of 
the melting method is its simplicity and economy (Chiou and Riegelman, 
1971). It is relatively easy to prepare melts and the equipment required is 
easily available and relatively cheap, keeping the cost low. Even though the 
melting temperature can be high, the drug/carrier mixture is only subjected to 
an elevated temperature for a short period of time, which enables thermolabile 
drugs to be processed (Leuner and Dressman, 2000). As compared to the 
solvent method, environmental aspects such as the use of organic solvents and 
potential health concerns from possible residual solvents are avoided (Fahr 
and Liu, 2007). In addition, the drug/carrier mixture solidifies relatively fast, 
enabling short evaluation time, which is highly desirable when screening a 
large number of formulations. 
 
C. Modification of drug release 
 The United States Food and Drug Administration (US FDA) defines 
modified release dosage forms as having drug release characteristics of time 
course and/or location that could accomplish therapeutic objective or 
convenience not offered by conventional dosage forms such as solutions and 
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immediate release dosage forms (Food and Drug Administration, 1997). 
Modified release solid oral dosage forms include both delayed and extended 
release drug products. A modified release product/dosage form usually 
consists of a portion of drug that is released immediately to achieve the 
desired therapeutic response, followed by a slower release of the remaining 
dose resulting in prolonged therapeutic effect (Aulton, 2007).   
 
1. Design of modified release drug delivery systems 
 Most of the modified release drug delivery systems fall into three 
broad categories, namely matrix, membrane controlled (or reservoir) and 
osmotic systems (Qiu, 2009). The matrix delivery system consists of the drug 
that is homogeneously dissolved or dispersed in a rate controlling matrix 
material that can be hydrophilic or hydrophobic. Hydrophilic matrix consists 
of water soluble and/or swellable materials while the hydrophobic matrix 
consists of water insoluble materials, usually with minimal swelling. In a 
membrane controlled system, the core containing the solid drug or highly 
concentrated drug solution is surrounded by a film or membrane of a rate 
controlling material. The osmotic pump system relies on the driven influx of 
water through a semi-permeable membrane (Rathbone et al., 2002). The 
dissolved drug is forced out of an orifice in the device by the osmotic pressure 
generated within the device. 
Drug release through these delivery systems generally involves one or 
a combination of the following mechanisms: drug diffusion (through pores of 
a barrier, tortuous channels or a viscous gel layer), system swelling (followed 
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by diffusion and/or erosion and dissolution) or osmotic pressure induced 
release (drug solution forced out of the system) (Qiu, 2009). 
For spray congealed microparticles, a proposed mechanism of drug 
release from a microparticle is illustrated in Figure 5. At the initial stage of 
contact with water, the surface drug (if water soluble) dissolves and gives a 
‘burst effect’. The outer polymer matrix hydrates and swells to form a gel 
layer which acts as a diffusion barrier. Over time, water gradually diffuses into 
the inner core. The drug particles within dissolve and diffuse out through the 
gel layer. The latter may erode and further enhance drug release. If the drug is 
poorly water soluble, it is released as particulates by erosion of the matrix, 
followed by dissolution of the drug in the gastrointestinal fluid. Following 
erosion, the new surface area exposed hydrates and forms a new gel layer. 
 
 
Figure 5. Schematic illustration of (a) microparticle formed from spray 





















2. Advantages and disadvantages of modified release dosage form 
 The major advantage of the modified release dosage form over 
conventional dosage form is the improved control over plasma drug 
concentration, allowing a sustained therapeutic effect (Abdul et al., 2010). 
This potentially leads to better treatment regime of chronic illnesses, reduction 
in the side effects of medications related to high initial peak plasma 
concentrations and a decrease in the total overall amount of drug to be 
administered (Wen and Park, 2010). It also improves patient compliance as the 
frequency of doses required is reduced while achieving similar therapeutic 
response (Tungaraza et al., 2013). The incidence and severity of localised 
gastrointestinal side effects produced by ‘dose dumping’ of irritant drugs can 
also be avoided. Lastly, there is the potential of greater cost savings for 
patients due to better disease management and pharmaceutical companies will 
benefit from patent life extension and product exclusivity in the market (Davar 
and Ghosh, 2010).  
 However, modified release dosage forms are not without their 
limitations. The variable physiological factors in the gastrointestinal tract 
(GIT) such as pH, food, enzyme activities and gastric transit rates, often 
interfere with drug release from modified release dosage forms (Aulton, 
2007). There is a risk for the dosage form to be lodged at some sites along the 
GIT as it moves down, producing a localised area of high drug concentration. 
As the modified release dosage forms normally contain a larger amount of 
drug, there is a possibility of overdosage if the integrity of the dosage form is 
compromised, which may, in some rare cases, even lead to death (Jayanthi et 
al., 2011; Schier et al., 2003).     
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3. Polyethylene glycols as matrix material  
Polyethylene glycols (PEGs) are water soluble synthetic polymers 
composed of repeating oxyethylene (-OCH2CH2-) units, with the ends of the 
polymer chain terminating with hydroxyl groups. They have been used 
extensively as hydrophilic matrices due to their water solubility/miscibility, 
low toxicity, low melting point (approximately 55 to 65 °C), low cost (Craig, 
1990; Leuner and Dressman, 2000), low absorption in the gastrointestinal tract 
and compatibility with most drugs (Chiou and Riegelman, 1971). Polyethylene 
glycols have been used in many solid dispersion applications (Vasconcelos et 
al., 2007). At room temperature, PEGs of molecular weight 3000-20,000 are 
solids. They exist as white or off-white free flowing powders (Rowe et al., 
2009). If PEG of very low molecular weight is used, this can lead to a product 
with a sticky consistency that is difficult to formulate into a pharmaceutically 
acceptable product. As the molecular weight of PEG increases, so does its 
viscosity. In light of this, PEGs of molecular weight 4000-6000 are the most 
frequently used. These polymers consist of two parallel helices and it was 
postulated that significant amounts of drug could be trapped in the helical 
interstitial spaces during solidification of the PEG-drug melts (Chiou and 
Riegelman, 1971). In this molecular weight range, the water solubility of PEG 
is still very high and the PEG matrices enable high rates of drug dissolution 
(Leuner and Dressman, 2000). The large molecular size of PEG favours the 
formation of thermodynamically stable solid solutions but other factors such 
as high viscosity, supercooling and physicochemical interaction between the 
drug and the polymer may contribute to the formation of metastable solid 
solutions if the PEG-drug melts are solidified rapidly (Chiou and Riegelman, 
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1971; Janssens and Van den Mooter, 2009). Rapid solidification retards the 
crystallization of the drug due to reduced solute migration and the difficulty in 
nucleation of the drug in the viscous medium (Buckley, 1951; Fox, 1963). The 
interaction between drug and PEG may also play a role in preventing 
crystallite growth (Chiou and Riegelman, 1971). The amorphous form of the 
drug will exhibit higher dissolution rate compared to its crystalline 
counterpart. The use of PEG in the spray congealing process also provides 
other benefits. PEG, being hydrophilic, makes it less likely for the spray 
congealed microparticles to stick to the chamber surface, resulting in a 
potentially higher yield. The cleaning of the processor is relatively simple and 
easy with the hydrophilic rather than lipophilic materials used, leading to 
shorter total manufacturing time. Therefore, PEG is deemed to be an ideal 
carrier for poorly water soluble drugs in spray congealing. A major 
disadvantage of PEG is its laxative effect, when consumed especially at large 
doses, which may lead to diarrhea.  
 
4. Excipients for drug delivery system modification 
4.1. Hydroxypropyl methylcellulose  
Celluloses are naturally occurring polysaccharides, consisting of high 
molecular weight unbranched chains, in which the saccharide units are linked 
by β-1,4-glycoside bonds (Leuner and Dressman, 2000). Hydroxypropyl 
methylcellulose (HPMC), also known as hypromellose, consists of mixed 
ethers of cellulose with each glucose unit having three hydroxyl groups that 
can be derivatized with methyl and hydroxypropyl substituents. These semi-
synthetic cellulose derivatives have a wide range of commercial applications 
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due to their good gelling and film-forming properties which are independent 
of pH (Vazquez et al., 1992). In pharmaceutical products, HPMC is commonly 
used as tablet coating polymer, binder in granulation, matrix polymer for 
controlled release of drugs and suspending or thickening agent in liquid 
preparations (Dow, 2002; Rowe et al., 2009). It exists as a white or creamy-
white fibrous or granular amorphous powder.  
 
4.2. Methylcellulose 
 Methylcellulose (MC) is a long chain substituted cellulose in which 
approximately 27–32 % of the hydroxyl groups are converted to methyl ether 
(Rowe et al., 2009). In tablet formulations, MC is used sometimes as a binder 
and may be applied to produce sustained release preparations. It is able to 
swell when hydrated into a clear to opalescent, viscous, colloidal solution 
(Kamel, 2008). Methylcellulose exists as a white, fibrous powder or granules. 
It is practically odorless and tasteless. 
 
4.3. Ethylcellulose 
 Ethylcellulose (EC), an ethyl ether of cellulose, is a long chain 
polymer of beta-anhydroglucose units joined together by acetal linkages 
(Rowe et al., 2009). It is a non-ionic polymer, pH insensitive and insoluble in 
water. The main use of ethylcellulose in oral formulations is as a hydrophobic 
coating agent for tablets and granules. However, modified release tablet 
formulations may also be produced using ethylcellulose as a matrix former. It 





 Polyvinylpyrrolidone (PVP), also known as povidone, is a synthetic 
hydrophilic polymer consisting of linear 1-vinyl-2-pyrrolidinone groups 
(Rowe et al., 2009). It has been used as binder in tablet formulations and also 
as viscosity-increasing agent in topical and oral preparations. Povidone has 
also been used to prepare sustained release preparations in pharmaceutical 
products (Bühler, 2004). Povidone exists as a fine, white to creamy-white 
coloured, odourless and hygroscopic powder. 
 
D. Polymer rheology  
1. Importance of polymer rheology in the pharmaceutical industry   
Polymer rheology plays a crucial role in determining the applicability 
of a polymer in processing and product manufacture. In recent years, there has 
been increasing interest in the investigations on the effects of polymer 
rheology on pharmaceutical processes involving liquids, whether in the form 
of solutions or melts (Barnes et al., 1989). Many pharmaceutical processes 
such as hot melt extrusion (Harold F. Giles Jr et al., 2005; Shah et al., 2013) 
and spray congealing (Hincal and Kaş, 1994; Maschke et al., 2007), and 
products such as solid dispersions (Chiou and Riegelman, 1971; Janssens and 
Van den Mooter, 2009), suppositories (Aulton, 2007) and pessaries utilize 
polymer melts. As such, an understanding of the rheological behaviour of 
these melts is important for successful process development and formulation 
of the desired product (Berry and Schott, 2011; Han, 2007). Although 
polymers have been studied over the years, polymer rheology is a particularly 
difficult subject to fully appreciate (Barnes et al., 1989). Most pharmaceutical 
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formulations have multi-components, such as matrix materials, additives and 
active pharmaceutical ingredients and they collectively make the rheological 
profiles of composite polymer melt suspensions complex and difficult to 
classify.  
The viscosity of polymer melt suspensions can be expressed by 
Einstein’s equation where the resultant viscosity (η) is a function of the 
viscosity of the suspending liquid or molten polymer (ηo), Einstein coefficient 
(kE) and volume fraction of suspended particles (ϕ) (Fried, 2003): 
η = ηo (1 + kEϕ)                                                                                 (1)                                                                                                                                                                                                                                                                                                                                                                                                      
The Einstein coefficient depends on the geometry and orientation of the 
entities that make up the dispersed phase, e.g. fibres and other non-spherical 
particles. The viscosity of the composite polymer melt suspension can be 
variable given that fibrous cellulosic additives such as HPMC, MC and EC 
particles can have assorted orientations in the molten polymer. Therefore, to 
ensure a higher productivity rate and a product of consistent quality, it is 
essential to employ an analytical tool capable of evaluating the viscosities of 
polymer melt suspensions.  
 
2. Application of multivariate analysis in polymer rheology 
Viscosity data are typically analysed by comparing single 
measurement points of different liquid formulations or observing plotted 
viscosity graphs for trends. Even though different techniques are used to 
extract information from the different viscosity profiles, it may be rather 
complex and time-consuming when many formulations are involved and the 
plots overlap with one another. Conventional statistical methods, such as 
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analysis of variance (ANOVA), allow the comparison of each data point in 
relation with other points at a particular temperature. However, no good 
method is available to consider the whole rheological profile and provide a 
comprehensive representation over a temperature range. Therefore, to further 
distinguish the viscosities of the composite polymer melt suspensions, 
multivariate analysis may be the best approach. Multivariate or chemometric 
analytical solutions have been increasingly used in different pharmaceutical 
applications to process data which are usually large and too complex to be 
easily interpreted (Gabrielsson et al., 2002). One of such method is principal 
component analysis (PCA) which allows the visualisation of the most 
important information contained in the data set (Esbensen et al., 2002). 
Principal component analysis has been applied in the pharmaceutical industry 
to detect differences in production batches when process parameters are 
changed (Roggo et al., 2005), evaluate characteristics of excipients (Dumarey 
et al., 2011; Persson et al., 1999), assess effects of formulation parameters on 
granule and tablet properties (Benkerrour et al., 1984; Giry et al., 2009) and in 
the non-pharmaceutical industries to determine the impact of processing on 
food and correlate physicochemical properties of materials (Christoffersson et 



























HYPOTHESIS AND OBJECTIVES 
Polyethylene glycols possess properties that are amenable to spray 
congealing. The use of HPMC as an additive in the spray congealing process 
has not been comprehensively studied. There is little information on the 
impact of various grades and concentrations of HPMC as well as other 
additives on the rheological properties of molten PEG mixtures and the 
properties of PEG matrix, drug and resultant microparticles. A greater insight 
and understanding of the above will enable the novel application of HPMC-
PEG matrix as a drug carrier in spray congealing. 
 
Hypothesis 
The viscosity of molten PEG mixture is dependent on the 
concentration, as well as particle size of HPMC incorporated as an additive. 
Drug release from spray congealed PEG microparticles is dependent on drug 
crystallinity as well as swellability of the microparticle matrix. These two 













The objectives of this study were: 
1. To screen various grades of polyethylene glycol (PEG) for suitability 
as matrix material for delivery of drug. The selected PEG grade would 
be used to produce the solid dispersions and spray congealed 
microparticles. 
 
2. To evaluate various types of additives that are commonly used in the 
pharmaceutical industry for formulating modified release matrix. An 
appropriate additive would be identified for use. 
 
3. To investigate the impact of various grades and concentrations of 
selected additive on the rheological properties of the molten mixtures 
using surface plots and principal component analysis.   
 
4. To study the impact of various grades and concentrations of selected 
additive on the physicochemical properties of PEG matrix, MNZ and 
spray congealed microparticles. 
 
5. To develop and produce metronidazole tablets containing spray 































1. Active pharmaceutical ingredients 
Metronidazole (MNZ, m.p. 158 to 160 °C, m.w. 171.2), a yellowish 
crystalline powder (Sunward Pharmaceutical, Singapore), and rifampicin (RIF, 
m.p. 183 to 188 °C, m.w. 823.0), a reddish amorphous powder (Taizhou 
Tianrui Chempharm, Taizhou, China), were used as model drugs in this study. 
Metronidazole is used in the treatment of Clostridium difficile infection in the 
colon where sustained release of MNZ is desirable. Being amorphous, 
rifampicin allowed the impact of matrix swelling on drug dissolution to be 
studied without the confounding effect of drug crystallinity.  
 
2. Matrix materials and additives 
Polyethylene glycols of different molecular weights (PEG 1500, 3350 
and 6000, m.p. 53-59 °C) were supplied by Clariant (Germany). 
Hydroxypropyl methylcellulose (HPMC) of 4 different series (K: K100M, 
K15M, K4M, K100 LV; E: E4M, E50 LV, E15 LV; F: F4M, F50 LV; 
Methocel: vLV) were obtained from Dow Chemical (USA). The properties of 
the various HPMC grades are listed in Appendix 2. Other additives used were 
polyvinylpyrrolidone K90 (PVP K90; ISP Technologies, USA), methyl 
cellulose 13-18 cps (MC; Tokyo Chemical Industry, Japan), ethyl cellulose 
90-110 cps (EC; Tokyo Chemical Industry, Japan), silicon dioxide (SiO2; Fuji 
Chemical Industry, Japan), magnesium stearate (MgSt; Productos Metalest, 
Spain), dicalcium phosphate (DCP; Rhodia, USA), citric acid (Merck, 
Germany) and sodium oleate (BDH Chemicals, England).  
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3. Dissolution media 
Hydrochloric acid (Schedelco, Singapore), potassium chloride, 
potassium dihydrogen phosphate, sodium hydroxide (Merck, Darmstadt, 
Germany) and deionised water were used in the preparation of the buffers.   
 
B. Methods 
1. Preparation of physical mixtures 
Physical mixtures corresponding to the microparticle formulations 
were prepared. The various components were accurately weighed and mixed 
in a clear plastic bag by shaking the content of the bag in a particular 
sequence. Visible clumps were broken down by applying pressure with a 
pestle before further mixing. The mixed powders in plastic bags were then 
sealed tightly and kept at 25 °C in an airtight container with silica beads until 
further analysis. 
 
2. Preparation of molten mixtures 
An appropriate amount of PEG was weighed in a glass beaker and 
transferred into a pre-heated oven (UL 40, Memmert, Schwabach, Germany) 
at 70 °C to form a melt to which HPMC and/or MNZ was then added. The 
mixture was stirred to obtain a homogeneous dispersion. Both HPMC and 
MNZ were poorly soluble in molten PEG and existed predominantly as 






3. Preparation of microparticles by melting method and milling 
3.1. Preparation of solid dispersions  
The melting method, which could be carried out easily, was employed 
to simulate the spray congealing process. Appropriate amount of PEG was 
weighed in a glass beaker and heated in an oven (UL 40, Memmert, 
Schwabach, Germany) at 80 °C to obtain a melt to which MNZ with/without 
HPMC was added. The mixture was stirred to obtain a homogeneous 
dispersion before being poured quickly into a 9 cm petri dish to form a layer 
of solid dispersion and rapidly cooled in the refrigerator (Bosch, Gerlingen, 
Germany) at 5 °C for 24 hours to allow solidification of the molten mixture. 
The resultant solid dispersion was removed from the petri dish and stored in a 
desiccator inside the deep freezer at -20 °C (Kelvinator Opal, Kelvinator, 
USA) to prevent thermal and moisture effect. Each formulation was prepared 
in triplicates.  
 
3.2. Conical screen milling of solid dispersions  
Prior to milling, the solid dispersions were broken into smaller slabs 
using mortar and pestle. Milling was carried out using a conical screen mill 
(Quadro Comil U5, Quadro Engineering Inc, Waterloo, Canada) with 
rectangular-bar impeller and grater-bore screen of progressively smaller 
aperture sizes (2769, 1575 and 1016 μm) operated at 1500 rpm. The slabs 
were milled for about 1 minute with each screen size to minimise the amount 
of fines generated and to ensure minimal heat production that might melt the 




4. Preparation of microparticles by spray congealing 
The microparticles were prepared using a laboratory scale spray 
congealer (Mobile Minor 2000, Niro, Soeborg, Denmark) with a cylindrical 
chamber (internal diameter: 0.8 m, height: 1.6 m) and conical base (Figure 6). 
A pneumatic two fluid nozzle, with a 2.0 mm nozzle tip, was used for the 
atomisation of melt into the cooled chamber. The cooled chamber was 
maintained at 5-10 °C by introducing cool air produced from an air chiller 
(ALFA ST 21, Air Blue, Italy). Air was extracted from the chamber by an 
exhaust fan. Atomisation air temperature was set at 80 °C and an atomising air 
pressure of 2.5 bars was used.  
 
 
















The matrix material, PEG, was heated to about 20 °C above its melting 
point (i.e. 80 °C) in an oil bath. Metronidazole and/or HPMC were added to 
the molten PEG and magnetically stirred to obtain a uniform mixture, which 
was then delivered to the spray nozzle using a peristaltic pump (Masterflex, 
Cole-Parmer, USA) at a rate of 20 mL/min. Larger spray droplets which 
solidified in the cooled chamber were collected in the bottom product 
collection vessel. These microparticles collected (useful fraction) were stored 
in polyethylene bottles at 25 °C. Fine particles (usually smaller than 10 µm) 
were classified out using a cyclone and collected in the fines collection vessel.  
 
5. Preparation of tablets with spray congealed microparticles 
 Tablets were prepared by direct compression using either a manual 
single station tablet press (NP-RD10, Natoli, USA) or a rotary tablet press 
(Courtoy, GEA, Belgium) using a 14 mm round flat-faced bevelled punches 
and die set, where appropriate. The manual tablet press was used to screen 
tablet formulations and selected formulations were then compacted using the 
rotary tablet press for in-depth studies. Different proportions of MNZ-loaded 
microparticles and lactose as filler were first mixed to obtain a homogeneous 
blend. Magnesium stearate, 1 %, w/w, as lubricant, was then added and mixed 
uniformly. One gram of the resultant powder blend was individually weighed 
out for compaction. The tablets prepared were allowed to recover for at least 
24 h before use at 25 °C. Various profiles of compression force and ejection 
force were generated from the instrumented rotary tablet press using a data 
acquisition and analysing system (CDASS, Puuman, Finland) with the aid of a 
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small pressure cell and transducers. The purpose was to investigate the optimal 
compression force and ejection force for tablet production. 
 
6. Characterisation of the physical mixtures, molten mixtures and 
microparticles 
6.1. Particle size analysis of particles produced by melting method and milling 
The powder sample of milled particles was sized using a mechanical 
sieve shaker (Retsch, VS 1000, Haan, Germany) with a stack of 4 sieves (500, 
355, 250 and 125 μm) and a base plate (Endecotts BS410, London, England). 
The sieves were individually weighed (W1) and arranged with the largest 
aperture size at the top and the base plate at the bottom of the stack. A known 
amount of the powder sample was poured onto the top sieve and stack vibrated 
at 1 mm amplitude for 10 minutes. Each sieve containing a specific powder 
fraction was weighed again (W2). The weight of each powder fraction was 
determined from the difference between W1 and W2. Triplicated analyses were 
carried out and the results averaged. The cumulative percentage weight 
undersize plot was then constructed. The size span, SX, was calculated from: 
SX = (d90-d10)/d50                                                                              (2)                                                                                                                                                                                                                                               







of the cumulative particle size distribution respectively. The median particle 
size is indicated by the d50 value. The size span represents the spread of the 
size distribution of the particles, where a larger size span value indicates a 





6.2. Particle size analysis of microparticles produced by spray congealing  
Measurements of spray congealed microparticle size of the useful yield 
fraction were determined by laser diffractometry (LS230, Coulter, USA) with 
a dry powder module. The laser diffractometer was used instead of the sieves 
because the sizer was more sensitive to the relatively small spray congealed 
microparticles. The dry powder module was employed because the 
microparticles were free flowing and a suitable suspending liquid was not 
easily identified. The particle sizes, d10, d50 and d90, were determined. The size 
span was calculated using Equation 2. Size measurements were carried out in 
triplicates for each batch and the results averaged.   
 
6.3. Determination of total yield and useful yield of spray congealed 
microparticles 
The total mass of the recoverable spray congealed product consisted of 
microparticles collected from the bottom product and the fines collection 
vessels. The total yield (%, w/w) was determined by dividing the total mass of 
recovered product with the mass of starting material. The useful fraction was 
composed of the product collected from the bottom product collection vessel. 
The useful yield (%, w/w) was calculated by dividing the mass of the useful 
fraction with the mass of the starting material. The mass of starting material 
used was determined by weighing the container of molten material before and 






6.4. Assessment of morphology of microparticles 
The morphology of the microparticles was visualised using a scanning 
electron microscope (JSM-6010LV, Jeol, Japan). Microparticles were 
mounted on aluminium studs using conductive carbon tapes and examined at 
1.5 kV under vacuum using a backscatter detector. The shape of the 
microparticles was evaluated by placing the microparticles on a glass slide for 
examination under a light microscope attached to a camera (BX61, Olympus, 
Japan) with an image acquisition system (Micro Image, Olympus, Japan). The 
shape was expressed by the aspect ratio (i.e. ratio of width to the length of the 
particle, determined by the image acquisition system), where a value of unity 
indicates a perfect sphere while higher values indicate deviation from a perfect 
sphere. At least ten spray congealed microparticles from the useful fraction in 
each batch were measured for their aspect ratios and the results averaged. 
 
6.5. Swelling analysis of microparticles 
The microparticles were placed on a glass slide. A cover slip was then 
placed over the microparticles. Water was passed through the slide at a 
constant rate of 0.25 mL/min at room temperature of 25 °C and the effect of 
water on the microparticles was captured using a high speed video camera 
(MotionPro HS-3, Redlake, USA) connected to an imaging system 
(MotionPro Central, Redlake, USA). The extent of swelling and rate of 
erosion of microparticles were determined as follows: 
Extent of swelling (%) = (dm – di)/di                                      (3)                                              
where di and dm refer to the initial dimension of the particle before contact with 
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water and the maximum dimension of the particle after contact with water 
respectively.  
Rate of erosion (µm
2
/s) = Si/t                                                      (4)                                                                                                                       
where Si is the cross-sectional area (top view) of the microparticle before 
contact with water, while t refers to the time taken for the microparticle to 
completely erode after contact with water. Microparticles were sieved into 
three size fractions (< 125 µm, 125 to 250 µm and >250 µm) for swelling 
analysis. At least 10 microparticles in each batch were used in the above 
measurements and the results averaged.  
 
6.6. Viscosity measurement of molten mixtures 
The viscosity of the molten mixtures was determined using a 
rheometer (AR-G2, TA Instruments, USA) with a parallel plate system (20 
mm diameter) with a gap of 1000 µm and temperature range of 70-120 ºC. 
Each sample was transferred to the rheometer plate and excess amount 
removed with a spatula. The measurements were carried out in triplicates and 
the results averaged. Unless stated otherwise, the viscosity values reported 
were determined at 80 ºC and shear stress of 6.37 Pa. 
 
6.7. Thermal analysis  
The thermal characteristics of single components, physical mixtures 
and spray congealed microparticles were determined using a differential 
scanning calorimeter (DSC-60, Shimadzu, Japan). A sealed aluminium pan 
loaded with sample was placed in a DSC furnace and heated from 20-200 °C 
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at a rate of 5 °C/min. An empty sealed aluminium pan was used as a reference. 
Measurements were carried out in triplicates and the results averaged. 
 
6.8. X-ray powder diffraction (XRD) analysis 
The crystallinity of single components, physical mixtures and spray 
congealed microparticles were studied using an x-ray powder diffractometer 
(XRD-6000, Shimadzu, Japan) with Cu Kα radiation (λ = 1.5406Ǻ), voltage of 
40 kV and current of 30 mA. The scanning angle (2 ) ranged from 10 to 35° 
with a scanning rate of 2 °/min. Measurements were performed in triplicates 
and the results averaged.  
Samples were stored at 25 °C and 30 % relative humidity. XRD 
spectra of the samples were obtained periodically to monitor for changes in 
drug (MNZ) crystallinity over time. The intensity of the major peak obtained 
at 12.5° corresponds to MNZ crystallinity and was used to determine the 
percentage crystallinity of MNZ in the sample (Brittain, 2003). The percentage 
reduction in crystallinity of MNZ in spray congealed microparticles was 
calculated from:  
Percentage reduction in MNZ crystallinity (%) = (Pm - Pp)/Pm x 100   (5)                                     
where Pm and Pp are the peak intensities of the physical mixture and the 
corresponding microparticles at 12.5°, respectively.  
 
6.9. Raman spectroscopy 
Raman spectroscopy was used to elucidate the solid state status 
(crystalline, amorphous or molecular dispersion) of the drug and the 
homogeneity of the drug distribution in the microparticles. The single 
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components and microparticles were spread respectively on a glass slide and 
examined using a Raman spectrometer (XploRA, Horiba Scientific, France), 
equipped with a 532 nm He/Ne laser source (30 mW), 1200 1/nm grating and 
a microscope system (BX 41, Olympus, Japan). Measurements were taken at 
the apex of the particle, where appropriate. Spectra collection was performed 
at room temperature under the following conditions: 10× microscope 
objective, 300 μm pinhole size, 100 μm slit width and 1 s exposure time. Each 
spectrum was derived from the average of three measurements. Drugs of 
crystalline structure are characterised by distinct and well-defined peaks in the 
spectrum.  
To investigate the homogeneity of the drug distribution in the 
microparticles, measurements were taken at 20 different positions (in a square) 
on the particle in a systematic manner. Similar spectra obtained indicate that 
the drug is uniformly distributed. 
 
6.10. Fourier transform-infrared spectroscopy (FT-IR) 
Interactions among MNZ, HPMC and PEG in the microparticles were 
investigated using FT-IR spectroscopy (Spectrum 100, Perkin Elmer, USA). 
Samples of the single components, physical mixtures and microparticles were 
each mixed with KBr in the weight ratio of 1:99 and ground in a mortar before 
being compressed into a disc, using a manual hydraulic press (Atlas Series, 
Specac, England) at 10000 kg for 5 min. Infrared spectra of the samples were 





6.11. Determination of solubility of metronidazole in PEG 
A known amount of PEG was melted in a reciprocal shaking bath 
(B602D Firstek, Aron Laboratory Instruments, Taiwan) at 80 °C. Excess MNZ 
was added to the molten carrier and allowed to equilibrate for 24 hours. The 
clear supernatant containing the dissolved drug was decanted into a petri dish 
and allowed to cool and solidify. A known amount of the solidified sample 
was dissolved in 0.1 M HCl and analysed for MNZ spectrophotometrically 
(UV 1201, Shimadzu, Japan) at 277 nm. Solubility was determined by the 
amount of MNZ dissolved per unit weight of PEG. Samples consisting of only 
PEG were also analysed to ensure no interference with the drug assay. 
Measurements were carried out in triplicates and the results averaged. 
 
6.12. Determination of drug content and encapsulation efficiency 
The MNZ-loaded microparticles were accurately weighed and diluted 
with 0.1 M HCl to a specified volume in a flask. The test mixture was agitated 
at 60 oscillations/min for 30 min in a shaker bath (M20S, MT/2, Lauda, 
Germany) at 65 °C. It was then cooled to room temperature before an aliquot 
sample was passed through a 0.45 µm membrane filter (Sartorius, Germany). 
The liquid sample was then diluted appropriately for drug assay by UV 
spectrophotometry (UV 1201, Shimadzu, Japan) at 277 nm. For RIF-loaded 
microparticles, phosphate buffer of pH 6.8 was used and the drug was assayed 
spectrophotometrically at 475 nm. Drug content was expressed as the amount 
of drug encapsulated per unit weight of microparticles. The drug content was 
determined in triplicates and the results averaged. The encapsulation 
efficiency (EE) was calculated as follows:  
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EE (%) = Wa/Wt x 100                                                               (6)                                                                                                         
where Wa is the actual drug content and Wt is the theoretical drug content, 
obtained from the amount of drug employed in the formulation. 
 
6.13. Construction of Beer-Lambert plot 
Accurately weighed amount of MNZ (100 mg) was dissolved in 0.1 M 
HCl (pH 1.2) or phosphate buffer solution (pH 7.4) and made up to volume in 
a 500 mL volumetric flask to prepare the standard solution. Different 
concentrations were then prepared by diluting appropriate aliquots of the 
standard solution. The drug was assayed spectrophotometrically (UV 1201, 
Shimadzu, Japan) at 277 nm and 319 nm for pH 1.2 and pH 7.4 respectively 
and the calibration plots constructed from the average values of triplicate 
determinations. For RIF, the drug was dissolved in phosphate buffer solution 
(pH 6.8) and assayed spectrophotometrically at 475 nm. 
 
6.14. Drug release study of microparticles 
The different batches of microparticles were sieved to obtain samples 
with similar median particle sizes. Drug dissolution rates for pure drug and 
equivalent amounts of microparticles were determined respectively, in 
phosphate buffer (pH 7.4) using the United States Pharmacopeia (USP) 
dissolution test method (Apparatus 2) with paddles rotating at 50 rpm. A 
dissolution test unit (9ST, Caleva, England) with an automated sampler 
(DataCheck, Caleva, England) was used. The volume of dissolution medium 
used was 900 mL, maintained at 37 °C. Samples of 6 mL were withdrawn at 
different time intervals from each dissolution vessel and assayed 
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spectrophotometrically for MNZ at 319 nm. The loss of medium was taken 
into account when calculating drug released into the medium. The percentage 
of drug released with respect to the total drug content was calculated. 
Dissolution test was carried out in triplicates and the results averaged. For RIF 
and RIF-loaded microparticles, phosphate buffer of pH 6.8 was used and the 
drug was assayed spectrophotometrically at 475 nm. 
 
7. Characterisation of tablets 
7.1 Tablet thickness 
The thickness of tablets containing spray congealed microparticles was 
determined using a micrometer (Digimatic micrometer, Mitutoyo, Japan). At 
least three determinations from each batch were carried out and the results 
averaged.  
 
7.2 Tablet hardness 
The hardness of tablets containing spray congealed microparticles was 
determined using a hardness tester (HT1, Sotax, Switzerland). ). At least three 
determinations from each batch were carried out and the results averaged.  
 
7.3 Disintegration time 
The disintegration times of tablets containing spray congealed 
microparticles were determined using a tablet disintegration tester (DT2, 
Sotax, Switzerland). Deionised water at 37 °C was used as the disintegration 
media and the time taken for complete disintegration of the tablet was 
measured. The tablet was considered to have disintegrated completely when 
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no palpable mass remained in the apparatus. The disintegration tests were 
performed on six tablets from each batch and the results averaged.  
 
8. Statistical analysis 
 The results were analysed using one-way analysis of variance 
(ANOVA) at level of significance 0.05 with the aid of statistical analysis 
software (SPSS, version 13.0, USA), where appropriate. Principal component 
analysis (PCA) was performed on the rheological data using the statistical 
software Unscrambler (X 10.2 CAMO Software AS). PCA scores plot was 





















RESULTS AND DISCUSSION 
Part I. Screening of matrix material and additives 
 Molten mixtures and solid dispersions containing PEG and MNZ were 
prepared using the melting method for the screening of various grades of PEG 
(Table 2). The 3 PEG grades studied have different molecular weights (1500, 
3350 and 6000). 
 
Table 2. Formulations used for screening of various grades of PEG. 
Formulation code PEG (%, w/w) MNZ (%, w/w) 
Px 100 0 
PxM10 90 10 
PxM20 80 20 
PxM30 70 30 
PxM40 60 40 
PxM50 50 50 
PxM60 40 60 
In formulation code, x = molecular weight of PEG used (1500, 3350 or 6000); 
P = PEG; M = MNZ; the numerical digits after M indicate the percentage of 
MNZ used in the formulation.  
 
Various additives that are commonly used to prepare modified release 
products were screened. The criteria for the selection of suitable additives 
were based on excipient compatibility and appropriate resultant viscosity of 
the molten mixtures. The viscosity of the molten mixture comprising the 
matrix material and additive should be sufficiently low so as to enable a high 
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drug loading and yet be sprayable without clogging the spray congealer 
delivery tube and nozzle.  
 
A. Rheological properties of PEG with/without MNZ 
1. Influence of molecular weight of PEG on viscosity  
For spray congealing, the matrix material is typically melted at a 
temperature of 20 °C above its melting point. Since the melting points of the 
PEGs selected are around 60 °C, the viscosities of the molten PEGs in this 
study were determined at 80 °C. The type of flow of the various formulations 
will be further discussed in Part II. The viscosity of the molten PEG was found 
to increase non-linearly with increasing molecular weight of PEG (Figure 7).  
 
 
Figure 7. Viscosity of different molecular weight PEGs at 80 °C. 
 
Polymer chains of PEG are arranged as helices which may be extended 
or folded (Craig, 1990). Higher molecular weight PEGs have longer polymer 

























resistance to shear forces, resulting in increased viscosity. A lower viscosity 
matrix material is generally preferred in spray congealing as this allows for 
higher drug loading without affecting sprayability. 
 
2. Influence of temperature on viscosity of the molten PEG with/without drug 
Generally, the viscosities of the formulations decreased as the 
temperature increased. Across the temperature range, P6000 had the highest 
viscosity followed by P3350 and P1500 (Figure 8a). Viscosities of the matrix 
material without drug decreased almost linearly with temperature (r
2 
= 0.92, 
0.97, 0.96 for P1500, P3350 and P6000 respectively). Entanglement of 
polymer chains was reported to impede the flow of polymer, leading to higher 
viscosity (Fried, 2003). PEGs of higher molecular weight have longer chains 
and are more prone to entanglement, thereby exhibiting higher viscosity. 
However, as the temperature increases, the polymer chains gain sufficient 
kinetic energy and begin to disentangle, resulting in decreased viscosity. 
The viscosities of all the formulations containing MNZ are shown in 
Figure 8b-d. Drug content was observed to affect the viscosity of the various 
formulations to different extents. Viscosity was generally low for P1500M 
with 40 % and less MNZ, P3350M with 30 % and less MNZ and P6000M 
with 10 % MNZ; and the viscosity decreased slightly with the increase in 
temperature from 70 to 120 °C. When the drug content in the respective 
molten PEG was increased beyond the afore-mentioned concentrations, the 
viscosity was markedly elevated. As the amount of drug increases, the 
particles come into closer contact with one another and may aggregate or 




Figure 8. Viscosities of molten mixtures of PEG: (a) without MNZ and (b, c, 
d) with MNZ.  
Note: Standard deviation < 5 %. Error bars are omitted to prevent cluttering of 
the graphs.  
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more liquid becomes entrapped in the flocculated drug particles. For these 
formulations, the viscosity change was greater when the temperature was 
increased. The temperature at which the viscosity began to level off was 80 °C 
for P1500M, 105 °C for P3350M and 115 °C for P6000M. These critical 
temperature values are postulated to coincide with maximum disentanglement 
of the polymer chains and disaggregation of the MNZ particles. Under such a 
situation, there would be minimum resistance to flow, which explains the 
constant viscosity despite increase in temperature. The higher molecular 
weight PEG has longer chains and would need a higher temperature to provide 
the kinetic energy for maximum disentanglement. This effect was not seen at 
lower concentrations of MNZ, probably because the difference in viscosity 
over the temperature range was too narrow. 
 
3. Influence of viscosity and PEG grade on drug crystallinity in congealed 
matrix at different drug concentration  
According to the literature, drug crystallinity may be affected by the 
viscosity of the medium used (Zhang and Zhou, 2009). Hence, in this study, 
the effects of viscosity on reduction in MNZ crystallinity at different drug 
concentrations of the various formulations were evaluated (Figure 9). The 
PEG of lower molecular weight showed a greater reduction in MNZ 
crystallinity. Drugs were reported to incorporate as separate molecules into the 
helical structures of PEG (Dhirendra et al., 2009). As PEG of higher molecular 
weight has longer chain length, it is able to accommodate more drug 
molecules and facilitate their rearrangement to form crystalline structures, 




Figure 9. Viscosity of various formulations and the percentage reduction in 
MNZ crystallinity of corresponding solid dispersions. 
 
At low drug concentration (10 to 20 %), a slight increase in viscosity 
resulted in much greater reduction in MNZ crystallinity. However, at higher 
drug concentration (20 to 50 %), reduction in crystallinity remained relatively 
similar despite marked increase in viscosity. In the molten mixture, drug 
molecules were dispersed. Upon cooling, dispersed drug molecules would 
undergo molecular rearrangement to form the crystalline structure. A slight 
increase in viscosity at low drug concentration retarded the rearrangement of 
drug molecules, resulting in lower drug crystallinity. Viscosity of a 
formulation can retard the diffusion of the molecules towards the crystal 
interface for crystal growth to occur (Janssens and Van den Mooter, 2009). At 
high drug concentration, the molecules were in closer proximity to one 
















































































B. Crystallinity of PEG  
PEG 1500 existed as a white semi-solid powder, PEG 3350 as a white 
free flowing powder and PEG 6000 as white flakes. XRD spectra of these 
PEGs before (PEG 1500, PEG 3350, PEG 6000) and after (P1500, P3350, 
P6000) subjecting to the melting method are shown in Figure 10.  
 
 
Figure 10. XRD spectra of different PEG grades before and after subjecting to 
melting method. 
 
The intensities of the peak are indicative of the crystallinity of the 
sample. P1500 showed the greatest reduction in major peak intensities at 19.3° 
and 23.4° compared to P3350 and P6000. Both peak intensities for P3350 and 
P6000 were similar to those of PEG 3350 and PEG 6000 respectively. This 
indicates that the crystallinity of PEG 1500, but not PEG 3350 and PEG 6000, 
was reduced by the melting method. It was reported that the molecules of 
molten PEG were able to reorientate themselves to form helices that aligned in 
an orderly fashion leading to crystallisation (Dhirendra et al., 2009). Higher 
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molecular weight PEGs are able to form more stable crystalline helices as 
compared to lower molecular weight PEGs (Craig, 1990). This aptly explains 
why P1500 had lower crystallinity than P3350 and P6000.  
 
C. Impact of different grades of PEG on MNZ stability in solid dispersions  
Stability of the drug in the matrix material is an important 
pharmaceutical consideration. Drug crystallinity in P1500M increased after 





Figure 11. Crystallinity of MNZ in P1500M, P3350M and P6000M when 
freshly prepared and after storage for 3 months at 25 °C and 30 % RH. 
 
In contrast, there was insignificant change (p > 0.05) in drug 
crystallinity in both P3350M and P6000M after 3 months of storage for all the 
drug concentrations. The drug might exist in the crystalline state, amorphous 
state and as molecular dispersion in the solid dispersions. The amorphous state 


































Storage after 3 months at 25  C and 30 % RH
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crystalline state upon storage. The increase in drug crystallinity over time in 
P1500M indicated that the drug was present in the amorphous state. However, 
this does not imply that the molecular dispersion of the drug is absent. The 
presence of drug as molecular dispersion was investigated and will be 
discussed in later sections. Lower molecular weight PEGs, which are semi-
solid, may allow greater molecular mobility, resulting in greater molecular 
rearrangement and increased drug crystallinity (Vasconcelos et al., 2007). 
 
D. Rheological impact of additives on molten PEG 3350 
 The impact of various additives, such as hydroxypropyl 
methylcellulose (HPMC K15M), methylcellulose (MC), ethylcellulose (EC) 
and polyvinylpyrrolidone (PVP K90) on the viscosity of molten PEG 3350 
was investigated. The concentration of additives used was 5 % (w/w). Higher 
concentrations were not investigated in this preliminary screening of the 
additives. The addition of EC to molten PEG produced a suspension that 
segregated upon standing (Figure 12). The other additives, HPMC, MC and 
PVP, were well dispersed in PEG 3350. Ethylcellulose particles, being 
hydrophobic in nature, self-aggregated in molten PEG which is hydrophilic. 
Hence, EC was poorly dispersed in PEG 3350 and was not studied further.  
The viscosities of the remaining molten mixtures containing the other 
additives are shown in Figure 13. The viscosities are ranked in the following 
order: PEG with PVP > PEG with MC > PEG with HPMC. The additives all 





Figure 12. Appearance of molten PEG 3350 with PVP, HPMC, MC and EC 
(from left to right). 
 
 
Figure 13. Rheological profiles of molten PEG 3350 containing various 
additives at 5 % concentration. 
Note: Error bars are omitted to prevent cluttering of the graphs. 
 
The geometry and orientation of the dispersed particles and their 
interaction with one another will have an impact on the resultant molten 
mixture viscosity. Hence, PVP particles, having a greater interaction with one 
another and with PEG, exhibited increased resistance to shear forces, resulting 
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in the highest viscosity observed (Chen et al., 2002). Molten mixtures 
containing MC had slightly higher viscosity than those with HPMC at 
temperatures below 90 °C but the viscosities were relatively similar at 
temperatures above 90 °C. Both MC and HPMC are fibrous cellulosic 
materials. Hence, their impact on the viscosity of molten PEG was relatively 
similar. Different additives used increased the viscosity of molten PEG to 
varying extent. Thus, the selection of the appropriate additive is important for 
the spray congealing process so as to ensure low molten mixture viscosity 
required for good delivery and avoid clogging of the feed line. 
 
E. Summary for Part I 
The PEG grade had an impact on MNZ crystallinity. Solid dispersions 
comprising PEG of lower molecular weight showed lower MNZ crystallinity. 
Viscosity of the molten mixture played an important role in affecting the drug 
crystallinity at low drug concentration. This effect diminished at higher drug 
concentration. The amorphous and/or molecularly dispersed drug was 
thermodynamically more stable in PEG of higher molecular weight. HPMC 
was well dispersed in molten PEG 3350. The resultant molten mixture 
comprising 5 % HPMC had a suitable viscosity for spray congealing. It is also 
available in a wider range of grades compared to MC. Hence, PEG 3350 and 
HPMC were selected to be used in subsequent studies to further investigate 
their impact on the physicochemical properties of the molten mixture and 





Part II. Impact of HPMC on rheological properties of binary/ternary 
PEG melt suspensions 
An understanding of the behaviour of molten mixtures is essential to 
the preparation and development of pharmaceutical dosage forms (Malkin, 
1994; Sinko, 2011). A highly viscous molten mixture would pose a problem to 
the spray congealing process as clogging of the feed line and atomizer could 
occur. Therefore, the influence of HPMC on the viscosity of the molten 
mixtures at varying temperatures was investigated. 
 
A. Nature of PEG melt suspensions 
Appropriate amount of PEG was melted in a beaker at 70 °C and 
different concentrations (5, 10 and 15 %) and different grades (K100 LV, 
K4M, K15M and K100M) of HPMC were added to it. The molten mixtures 
were carefully stirred to obtain a uniform mixture for viscosity measurement. 
The rheograms of molten PEG 3350 with various grades and concentrations of 
HPMC are shown in Figure 14. The shear rate of molten PEG increased non-
linearly with increase in shear stress over the range of 0.5-3.5 Pa. The concave 
curve indicates pseudoplastic flow which is characteristic of polymer 
solutions. The PEG melt suspensions studied had relatively low concentration 
of HPMC particles. Hence, the melt suspensions resemble the flow of a 
polymeric solution. The polymer molecules disentangled as the shear stress 
increased and aligned in the direction of flow. At higher shear stress of more 
than 3.5 Pa, the molecules were fully aligned in the direction of the stress 
applied. At this stage, the flow curve tended towards linearity, indicating that a 




Figure 14. Shear rate of molten PEG 3350 and molten mixtures containing (a) 
5 %, (b) 10 % and (c) 15 % HPMC with varying shear stress at 70 °C. 
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The slope of the graph represents the fluidity of the formulation. 
Viscosity is the reciprocal of fluidity. Molten PEG without HPMC was the 
least viscous among all the formulations. At the same HPMC concentration, 
K100 LV, K4M and K100M generally had lower viscosity enhancing effect 
than K15M. 
 
B. Effects of various concentrations and grades of HPMC and temperature 
Ternary formulations were employed to investigate the influence of 
various grades of HPMC at different concentrations on the viscosities of PEG 
3350 melt suspensions containing MNZ (Table 3).  
 
Table 3. Composition of ternary formulations of PEG melt suspensions. 






1 75 5 20 
2 70 10 20 
3 65 15 20 
4 60 20 20 
5 55 25 20 
 
The viscosity of the formulations with HPMC concentrations from 5 to 
25 % could be determined by the rheometer except for a few grades of HPMC 
at very high concentrations. The PEG melt suspensions consisting of K100M 
above 15 % and F4M, K100 LV, K4M and K15M above 20 % were too 
viscous for accurate measurements. These few formulations appeared almost 
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like a semi-solid paste and would not flow. The formulations of F50 LV, E15 
LV, E50 LV, E4M and Methocel vLV were relatively less viscous even at 
high HPMC concentrations. Generally, the lower viscosity grades permitted a 
higher load of HPMC before becoming too viscous compared to higher 
viscosity grades. However, K100 LV, a low viscosity grade, did not permit 
high HPMC loading. Therefore, viscosity grades of HPMC and the viscosity 
of PEG melt suspensions were not well correlated.  
Surface plots were used to study the effect of HPMC concentration and 
temperature on the viscosity of the ternary formulations (Figures 15 and 16). It 
was observed that the viscosity of the formulations generally increased 
proportionally with HPMC concentration but inversely with temperature. A 
higher concentration of solids in the PEG melt retarded the flow of the melt, 
resulting in higher viscosity. On the other hand, an increase in temperature 
increased the kinetic energy of the molecules, resulting in greater molecular 
mobility and reduction in viscosity. A combination of both the HPMC 
concentration and temperature effects affected the viscosity of the PEG melt 
suspensions to the greatest extent. Viscosity values were markedly increased 
for all grades of HPMC when the concentration increased or a lower 
temperature was used. For all grades of HPMC, the increase in HPMC 
concentration resulted in a more drastic rise in the viscosity than changes in 
temperature. This implies that HPMC concentration was the primary factor 
affecting the viscosity of the PEG melt suspensions. Therefore, the control of 
viscosity of PEG melt suspension was more readily achieved by modifying the 
amount of solids rather than regulating the temperature of the process. The 




Figure 15. Surface plots of log viscosity of PEG melt suspension with 
temperature and HPMC concentration for (a) Methocel vLV, (b) F50 LV, (c) 





Figure 16. Surface plots of log viscosity of PEG melt suspension with 
temperature and HPMC concentration for (a) K100 LV, (b) K4M, (c) K15M 
and (d) K100M.  
 
Methocel vLV is a recently introduced grade of very low viscosity 
HPMC. Its viscosity is lower than that of E15 LV at 2 % concentration in 
water at 20 °C. However, the viscosity of the PEG melt suspensions consisting 
of Methocel vLV was consistently higher compared to the corresponding melt 
suspensions consisting of E15 LV (Figure 15). The surface plot of melt 
suspensions of Methocel vLV was found to be more comparable to those of 
F50 LV and E50 LV, indicating a similarity in viscosity between these grades 
when used in PEG melt suspensions. The HPMC viscosity stated in the 
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literature refers to the solution viscosity (Appendix 2). The solution viscosity 
of HPMC and its corresponding viscosity in polymer melt are different. 
Hence, the different HPMC grades suitable for substituting one another in an 
aqueous solution may not be so for a polymer melt. HPMC was practically 
insoluble in PEG melt and formed a suspension. Methocel vLV had similar 
HPMC particle size as E50 LV and F50 LV. This very likely accounted for 
their similarity in viscosity in the PEG melt. The effect of particle size of 
HPMC on the viscosity of PEG melt suspensions will be discussed in later 
sections. 
The E15 LV grade had the lowest solution viscosity among the 
different grades of HPMC (excluding Methocel vLV) (Appendix 2). 
Comparing the corresponding melt suspensions, those consisting of E15 LV 
also had the lowest viscosity. When the HPMC concentration of E15 LV was 
varied from 5 to 25 %, the change in melt suspension viscosity was the least 
compared with all other grades. Even with a high loading of 25 % w/w, the 
viscosity remained low compared with other grades at the same loading level. 
Therefore, the E15 LV grade would be useful in melt formulations where a 
high concentration of solids is needed. The melt dispersion could be more 
efficiently conveyed or atomised if the final melt liquid viscosity is not 
excessively high.  
Within the E-series of HPMC, the viscosities of the melt suspensions 
increased from E15 LV < E50 LV < E4M (Figure 15). This is in agreement 
with their corresponding solution viscosities (Appendix 2). The F-series also 
showed a similar trend with melt suspensions of F50 LV having a lower 
viscosity than F4M. 
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With the exception of K100 LV, the HPMC grades in the K-series 
showed similar trends in solution viscosity and melt suspension viscosity: 
K4M < K15M < K100M (Figure 16). For HPMC K100 LV, the results 
showed that viscosity at 20 % loading was similar to that of K15M but higher 
than that of K4M. This is in agreement with preliminary observations that the 
molten mixture comprising K100 LV had an unusually high viscosity. Among 
the HPMC grades in the K-series, K100 LV had the lowest solution viscosity 
(Appendix 2). This finding further substantiated that the viscosity of HPMC in 
polymer melts may differ from that in solution.  
The drawback of comparing the surface plots with one another is that 
trends are not easily distinguished. The comparison of different grades of 
HPMC at different concentrations and temperatures would also be more 
tedious and time-consuming. Therefore, multivariate analysis, in particular 
principal component analysis, was used to evaluate and compare the rheology 
of polymer melt suspensions (Part III). 
As mentioned previously, HPMC concentration was the primary factor 
affecting the viscosity of the polymer melt suspensions. The success of the 
spray congealing process is dependent on the viscosity of the polymer melt 
suspension. Therefore, it was of interest to investigate the effect of HPMC 
particle size and hydration of the HPMC particles on the viscosity of the melt 
suspension.  
 
C. Effect of HPMC particle size  
Figure 17a-b shows the median particle size and the particle size 
distribution of the various grades of HPMC. To investigate the effect of 
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HPMC particle size on the viscosity of PEG melt suspensions, the surface 
plots were converted to line plots (Figure 18).  
 
 






























Figure 17. (a) Median particle size (n=3) and (b) size distribution of various 
































































Figure 18. Line plots of melt suspension viscosities with increasing 







Within the F-series, the melt suspension viscosity of F50 LV was 
higher than that of F4M at each corresponding concentration from 5 to 15 % 
(Figure 18a). The particle size of F50 LV was found to be significantly lower 
than that of F4M (p < 0.05). The particle size distribution of F50 LV was also 
relatively narrower than that of F4M. At the same concentration, HPMC grade 
with smaller particles would be present numerically larger in the melt 
suspension. The larger number of particles retarded the flow of molten PEG, 
accounting for the above viscosity trend. At 20 % concentration, the viscosity 
of F4M surpassed that of F50 LV. Despite having a larger number of particles, 
F50 LV resulted in lower melt suspension viscosity than F4M. At higher 
concentrations, the HPMC particles were closer to one another and more likely 
to interact. Particle-particle interactions are dependent on the surface area 
available for contact, which in turn depends on the particle shape and size 
distribution. The particle shapes of the different HPMC grades were found to 
be variable, albeit generally elongated (Figure 19). Nevertheless, the trends 
observed suggested that particle-particle interactions were largely affected by 
particle size and particle size distribution. Collectively, the results indicated 
that HPMC grade with larger particle size and size distribution would exhibit 
greater particle-particle interaction at high HPMC concentrations, yielding 


















Figure 19. Photomicrographs of HPMC (a) E15 LV, (b) E50 LV, (c) E4M, (d) F50 LV, (e) F4M, (f) K100 LV, (g) K4M, (h) K15M, (i) K100M 





(a) (b) (c) (d) (e) 
(f) (g) (h) (i) (j) 
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Particle size and size distribution exerted more than one effect and its 
influence on melt suspension viscosity was not straightforward. Increase in 
particle size and size distribution favoured particle-particle interaction, which 
in turn increased viscosity. On the other hand, increase in particle size reduced 
number of particles for the same HPMC concentration and reduced retardation 
of flow. 
Interesting findings were observed with the E-series of HPMC. Having 
smaller particle size than E4M, E50 LV resulted in higher melt suspension 
viscosity than E4M from 5 to 15 % concentrations (Figure 18b). Above the 
concentration of 15 %, melt suspension viscosity of E4M was higher than that 
of E50 LV. The higher viscosity could be attributed to particle-particle 
interaction shown by E4M. However, the viscosity of E50 LV remained 
consistently higher than that of E15 LV at each corresponding concentration 
from 5 to 25 %. Since E15 LV had greater particle size than E50 LV, E15 LV 
was expected to exhibit greater particle-particle interactions and higher melt 
suspension viscosity than E50 LV at high concentrations. Nevertheless, this 
was not observed. The results alluded that E15 LV did not exhibit particle-
particle interaction. The median particle size of E15 LV (81 µm) was higher 
than that of E50 LV (73 µm) but lower than that of E4M (89 µm). Therefore, 
it could be postulated that a reasonable physical size was necessary for 
particle-particle interaction to occur. In the present situation, the HPMC 
should have median particle size greater than 81 µm before particle-particle 
interactions could occur. 
Within the K-series, particle size of K100M was significantly smaller 
than that of the other three grades (p < 0.05), with a slightly narrower particle 
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size distribution as well (Figure 17a-b). The melt suspension viscosity of 
K100M was consistently higher than those of K100 LV, K4M and K15M at 
each corresponding concentration from 5 to 15 % (Figure 18c). At 20 % 
HPMC concentration, K100 LV and K15M had higher viscosity than K4M 
even though the median particle sizes and size distribution for all three grades 
were similar (p > 0.05). The various HPMC grades consisted of fibrous 
particles of variable geometry (Figure 19). Particle-particle interaction was 
largely affected by particle size, and to a certain extent by the particle 
geometry. 
To gain a deeper understanding of the effects of HPMC particle size on 
viscosity of PEG melt suspensions, a further investigation using HPMC K15M 
of distinctly different particle sizes was carried out. The median particle size 
of the various HPMC mesh size fractions was determined from the size 
distribution curve obtained by laser diffractometry (Figure 20). A low 
concentration of HPMC (5 %) was employed so that the effect of HPMC 
particle numbers on PEG melt suspension viscosity can be observed clearly. If 
a high concentration of HPMC was used, the propensity for particle-particle 
interaction may mask the effect of HPMC particle numbers on melt 
suspension viscosity. Figure 21 shows the effect of particle size on the 
viscosities of melt suspensions. HPMC of the smallest size fraction (d50 of 33 
µm) had a melt suspension viscosity of 0.47 Pa.s. When the median particle 
size increased to 58 µm, the viscosity of the melt suspension decreased. As 
mentioned earlier, at the same concentration, HPMC with smaller particle size 
would be present in a numerically larger quantity which would retard the flow 








Figure 21. Viscosities of PEG melt suspensions containing HPMC of 
increasing particle size. 
 












































Increasing HPMC particle size
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particles dispersed in the same volume of molten PEG. The particles in the 
melt suspension were dispersed and existed as individual, separated particles. 
There was no continuous HPMC network. Collectively, these phenomena 
accounted for the drop in viscosity. When the median particle size was 
doubled (114 µm), it resulted in a significant spike in viscosity of the melt 
suspension (0.494 Pa.s, p < 0.05). The spike in viscosity supported earlier 
postulation that increased particle-particle interaction occurred when HPMC 
was of a certain particle size. At this stage, the HPMC network would be 
continuous, resulting in a great resistance to the flow of molten PEG. 
Interestingly, further increase in particle size led to a remarkable decrease in 
viscosity (p < 0.05). The results suggested that these larger HPMC particles 
interacted and formed clusters/aggregates in the melt suspension, resulting in a 
reversal of the continuous to discontinuous network. Furthermore, at the same 
concentration, larger HPMC particles would be present in a lower number 
which may be insufficient to form a continuous network. When the size of the 
HPMC particle became very large (275 µm), the viscosity increased slightly. 
As the particle size increased, the size of the cluster increased correspondingly 
to a level that retarded the flow of molten PEG, albeit to a lower extent than if 
a continuous network was formed. Clearly, the influence of particle size on the 
viscosity of PEG melt suspensions was not straightforward. 
 
D. Effect of water content in molten PEG 
The presence of inherent water in PEG after melting could have an 
impact on the viscosity of the molten mixture due to the water absorption and 
subsequent swelling of HPMC particles. The maximum capability of PEG to 
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withhold water was evaluated by adding different amounts of water to molten 
PEG, which was then left to solidify at ambient temperature. It was found that 
above 2 % water content, molten PEG could not solidify sufficiently. 
Therefore, to investigate the increase in viscosity due to water in molten PEG, 
various amounts of water were added to molten PEG (to a maximum of 2 %) 
and stirred thoroughly prior to the addition of 5 % HPMC. The smallest size 
fraction of HPMC K15M was employed because it had the highest surface 
area to volume ratio and largest number of particles per unit weight for water 
absorption. Figure 22 shows the water contents of the PEG melt suspensions 
and their corresponding viscosity values. The viscosity fluctuated between 
0.38 to 0.45 Pa.s, indicating that water content did not have any substantial 
impact on the viscosity of PEG melt suspensions containing HPMC. The 
increase in viscosity of the melt suspensions was more likely to be due to the 




Figure 22. Viscosity of PEG melt suspensions consisting of 5 % HPMC 
K15M and varying water content.  
Note: SD bars are too small to be seen. 



























E. Summary for Part II 
The viscosity grades of HPMC and the viscosity of PEG melt 
suspensions were not correlated. For all grades of HPMC, the amount of 
HPMC added to molten PEG was found to play a more dominant role than 
temperature in changing the viscosity of PEG melt suspensions. Particle size 
and size distribution of HPMC also played a role in the viscosity of melt 
suspensions. Smaller particles led to a greater viscosity rise than larger 
particles. HPMC exhibited a propensity for particle-particle interaction at a 
certain particle size, leading to the formation of a continuous network and 
higher viscosity. Above this particle size (with corresponding lower particle 
number), HPMC formed clusters, resulting in a discontinuous network and 
lower viscosity.  
 
Part III. Evaluation of polymer rheology using principal component 
analysis  
Surface plots are commonly used to visualise data three dimensionally. 
In part II, surface plots were used to understand the impact of HPMC 
concentrations and temperatures on the viscosities of the melt suspensions. 
Detailed comparison of the viscosities at each and every temperature and 
concentration between the various grades of HPMC was however very tedious 
and time-consuming. Therefore, the use of principal component analysis was 
explored to compare the viscosity profiles of the various formulations. Such 
analysis would also provide useful information on the possibility of 
substituting one HPMC grade with another without affecting the 
manufacturing process and final product. 
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A. Assessment of principal component analysis as a suitable analytical tool to 
evaluate viscosity profiles of melt suspensions 
The ability of PCA to differentiate viscosity profiles of different 
formulations was examined. Binary formulations of PEG with low (5 %) and 
high (25 %) concentrations of the ten grades of HPMC, were prepared and 
their viscosities were determined using a rheometer (Table 4). The viscosity 
profiles generated from the rheometer were then analysed using PCA. The 
scores plot generated from PCA was a two dimensional scatter plot which 
gave information about trends of the samples studied. The closer the samples 
were in the scores plot, the more similar they were. Conversely, samples far 
away from each other were different from each other. The plot was used to 
interpret differences and similarities among samples. The correlation between 
the viscosity profiles determined using the rheometer and the PCA scores plot 
was used to establish the suitability of PCA as an analytical tool for 
classifying the viscosity profiles of melt suspensions.  
The effect of temperature on the viscosity of low and high 
concentrations of various grades of HPMC was examined (Figure 23). Four 
distinct groups of viscosity profiles were observed. These groups were 
numbered 1 to 4. Group 1 represented the formulations whose viscosities were 
the highest and Group 4, the lowest. Melt of PEG alone had the lowest 
viscosity among the formulations. Groups 1 to 3 consisted of formulations 
with 25 % HPMC of various grades. This observation demonstrated that the 





Table 4. Composition of binary and ternary formulations of polymer melt 
suspensions. 
Formulations PEG (%, w/w) HPMC (%, w/w) MNZ (%, w/w) 
Binary    
Low 95 5 - 
High 75 25 - 
Ternary    
1 75 5 20 
2 70 10 20 
3 65 15 20 
4 60 20 20 




Figure 23. Viscosity profiles of the various formulations with increasing 
temperature. 
 
It is interesting to note that the viscosity profiles of the formulations 
with high HPMC concentration were grouped according to the E-, F- and K-
series with the exception of K100M. As mentioned previously, particle-
particle interaction predominated at high HPMC concentration. The viscosity 
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profiles suggested that the F-series generally had more extensive particle-
particle interactions compared to the K-series, followed by the E-series at 25 
% concentration. Within each series, it was difficult to rank the grades 
according to the extent of particle-particle interactions as their viscosity 
profiles intersected with one another at various temperatures. For example, 
viscosity profile of 25 % K15M intersected with 25 % K100 LV at 109 °C. 
The overlapping of viscosity profiles was also seen in Group 4, which 
consisted of 5 % HPMC of various grades. Within this group, viscosities of 
the various formulations were similar. The viscosity of a particular HPMC 
grade might not be consistently higher or consistently lower than that of 
another grade throughout the whole temperature range. This finding showed 
additional complexity of PEG-HPMC or HPMC-HPMC interactions at the 
different temperatures, resulting in difficulties to generalise.  
Interestingly, the viscosity profiles of formulations with 25 % HPMC 
(high concentration) generally exhibited a biphasic curve. This effect was not 
seen at 5 % HPMC (low concentration). The viscosity profile of PEG alone 
exhibited a linear curve. The point of deflection in the biphasic curve was 
postulated to coincide with maximum disentanglement of all the polymer 
chains of PEG. Under such a situation, there was a lower resistance to flow, 
which explains the smaller decrease in viscosity as temperature increased. The 
PEG chains disentangled easily when HPMC was not present or at low 
concentrations. A high concentration of HPMC possibly hindered the 
disentanglement of the PEG chains.  
Each formulation was given a code for ease of representation in the 
PCA scores plot (Table 5). The viscosity profiles of the binary formulations 
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were analysed using PCA and the corresponding scores plot of the 
formulations are shown in Figure 24.  
 
Table 5. Different formulations containing various grades of HPMC and their 
corresponding codes represented in PCA. 










E50 LV xEb 
E15 LV xEc 
F-series  
F4M xFa 
F50 LV xFb 
Special series  
Methocel vLV xM 










Figure 24. Scores plot of the viscosity profiles of binary formulations.  
Codes represent the different formulations as shown in Table 5. 
 
Each formulation consisting of triplicates was represented by 3 data 
points. In the PCA scores plot, four distinct groups of formulations were 
observed (circled). The low viscosity formulations clustered to the left while 
those of higher viscosities to the right. The formulations within each group in 
line plot (Figure 23) were compared with those in the scores plot and were 
found to match. The good correlation between the scores plot generated and 
viscosity profiles determined using a rheometer established that PCA was able 
to successfully compare various viscosity profiles and differentiate them into 
clusters of similar viscosities. Therefore, the use of better and faster analytical 
method, such as PCA, can be suitable for studying the viscosity profiles of 




for all grades  
 
25% E4M 
25% E50 LV 
25% E15 LV 
25% K100 LV 
25% K15M 
25% K4M 







B. Evaluation of ternary polymer melt suspensions using principal component 
analysis   
The ternary formulations consisted of MNZ and HPMC in molten PEG 
(Table 4). The scores plot of these formulations showed the presence of three 
clusters when their viscosity profiles were evaluated using PCA (Figure 25). 
All the formulations within the same cluster had comparable viscosity profiles.  
 
 
Figure 25. Scores plot of the viscosity profiles of ternary formulations.  
Codes represent the different formulations as shown in Table 5. 
 
Table 6 lists the formulations in the scores plot according to the 
clusters of low, moderate and high viscosities relative to each other. In the 
high viscosity cluster, HPMC grades K100 LV and K15M at a concentration 
of 20 % had viscosity profiles comparable with most of the other grades at 25 
%. Avoidance of high viscosity in melt suspension formulations required the 
HPMC concentrations to be below 20 % for K100 LV and K15M and below 
25 % for the other grades. In the moderate viscosity cluster, K4M and F50 LV  
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Low Moderate High 
Methocel vLV 5, 10, 15 20 25 
E15 LV 5, 10, 15, 20 25 - 
E50 LV 5, 10, 15, 20 - 25 
E4M 5, 10, 15 20 25 
F50 LV  5, 10 15, 20 25 
F4M  5, 10, 15 20 - 
K100 LV 5, 10 15 20 
K4M 5, 10 15, 20 - 
K15M 5, 10 15 20 
K100M 5, 10 15 - 
1) 
Numerical value denotes the concentration of HPMC used. 
 
grades had similar viscosity profiles at HPMC concentrations of 15 % and 20 
%. Thus, increasing the HPMC concentration from 15 to 20 % would not be 
effective in increasing the viscosity of the melt suspension. For all 4 grades of 
the K-series, HPMC concentration at 15 % resulted in similar melt suspension 
viscosities. Viscosity of E15 LV remained moderate even at 25 % 
concentration and comparable to other grades at lower HPMC concentrations. 
Hence, E15 LV would be the most appropriate grade to use when a need for 
high HPMC concentration, yet maintaining a suitable viscosity, is required. 
Being in the same cluster, all these grades at various concentrations can be 
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used interchangeably when a similar viscosity is required. In the low viscosity 
cluster, HPMC grades of E15 LV and E50 LV had similar viscosities when 
used at concentrations 5 to 20 %. HPMC E50 LV showed a remarkable 
increase in melt suspension viscosity, moving from low to high viscosity 
cluster, when HPMC concentration was increased beyond 20 %. This implied 
that the concentration used should be less than 20 % to avoid poorly flowable 
high viscosity formulations for this grade. The viscosities of Methocel vLV, 
E4M and F4M were similar when used at 5 to 15 %, thus allowing the use of 
higher HPMC concentrations without the concern of increasing formulation 
viscosity significantly. The HPMC grades in K-series were similar in viscosity 
with F50 LV at 5 and 10 %. It seemed that regardless of the grades in the K-
series, all of them can be used interchangeably.   
No particular trend was observed when comparing the scores plots of 
the ternary and binary formulations. It is vital to note in both plots that HPMC 
of low concentrations (5 %) were all grouped together. At higher 
concentrations (25 %), binary formulations were differentiated into more 
clusters compared to ternary formulations. The different grades (Methocel 
vLV, E50 LV, E4M, F50 LV) which were previously separated in scores plot 
of binary formulations were clustered together in scores plot of ternary 
formulations. This showed that addition of MNZ, despite in the same amount 
in all formulations, increased the melt suspension viscosities to different 
extents. It cannot be assumed that the viscosity trends will remain consistent 
when more components are added to the formulation. This observation 
reflected the complex interactions affecting viscosity when different 
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components are used in a formulation and reinforces the need of using PCA to 
evaluate the various formulations.  
The viscosity of polymer melt suspensions can be expressed by 
Einstein’s equation. Modelling of viscosity data was performed on the ternary 
polymer melt suspensions. However, the results did not indicate conformity to 
Einstein’s equation. The viscosity of the composite polymer melt suspension 
can be variable given that fibrous cellulosic additives such as HPMC particles 
can have assorted orientations in the molten polymer.  
 
C. Sprayability of ternary melt suspensions   
 Several formulations were selected from each cluster of low, moderate 
and high viscosity and were subjected to the spray congealing process to 
determine their sprayability. Sprayability in spray congealing refers to the 
ability to atomise a formulation of suitable viscosity to obtain a reasonable 
yield of microparticles without choking of the delivery system. Formulations 
in the low viscosity clusters (0.93 to 5.62 Pa.s) were successfully spray 
congealed. Above that viscosity, choking problems occurred. Hence, at a melt 
temperature of 80 °C, the highest formulation viscosity sprayable was 5.62 
Pa.s. Formulations in the low viscosity cluster were classified as sprayable 
while those in moderate and high viscosity were not sprayable.  
 
D. Summary for Part III 
Principal component analysis was found to be a suitable tool to 
evaluate viscosities of polymer melt suspensions as there is good correlation 
between the viscosity profiles obtained experimentally and the scores plot. It 
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was also able to differentiate the complex viscosity profiles of different 
formulations in an efficient and time-saving manner, and provided an 
excellent visualisation of the data. The ternary melt suspensions were 
classified into three clusters, namely low, moderate and high according to their 
viscosities. Formulations of ternary melt suspensions in the low viscosity 
cluster were found to be sprayable without choking the delivery system of the 
spray congealer. PCA enabled the selection of an appropriate grade and 
concentration of HPMC to achieve the desired viscosity in the pharmaceutical 
process. 
 
Part IV. Impact of various grades and concentrations of HPMC on the 
properties of congealed matrix with drug 
 As mentioned previously, the melting method followed by milling is a 
relatively simple and useful screening method especially when many 
formulations are involved. Moreover, it can be aptly used as a method to 
simulate the spray congealing process. In this part of the study, the matrix 
material, drug and additive were prepared and subjected to the above process 
using operation conditions comparable to those in spray congealing. The 
formulations of the solid dispersions prepared are shown in Table 7. 
 
A. Appearance of molten mixtures, solid dispersions and milled particles  
Molten mixtures were prepared from PEG 3350, MNZ and HPMC of 
different grades and concentrations. They appeared light to dark yellow in 
colour, relatively less viscous at 5 to 10 % HPMC compared to a grainy, 
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viscous paste at higher concentrations (15 to 25 %) (Figure 26a). The solid 
dispersions were off-white to light yellow in colour (Figure 26b). 
Table 7. Formulations containing PEG 3350 and MNZ with various grades 
and concentrations of HPMC. 






P80M20 80 20 0 
P75M20H5 75 20 5 
P70M20H10 70 20 10 
P65M20H15 65 20 15 
P60M20H20 60 20 20 
P55M20H25 55 20 25 
P = PEG 3350; M = MNZ; H = HPMC   
Note: PEG 3350 was selected from Part 1 of the study. The numerical digits 
after the alphabet indicate the composition of the formulation (i.e. P80M20 
represents 80 % of PEG 3350 and 20 % of MNZ in the formulation) 
 
 
Figure 26. (a) Molten mixture of PEG, MNZ and HPMC, (b) solid dispersion 
removed from the refrigerator and (c) particles produced after milling. 
 
The yellow colouration was due to MNZ (molten PEG was colourless). 
The formulations with 5 to 10 % HPMC were easier to mill. At 15 to 25 % 
HPMC, the solid dispersions appeared less homogeneous with grainy surfaces. 
They were also harder to mill. All the milled particles were relatively free 
(a) (b) (c) 
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flowing and had an off-white colour (Figure 26c). No yellow colouration was 
observed for the milled particles as they took on the colour of PEG, which is 
off-white in solid state.  
 
B. Relationship between particle size and the mechanical properties of 
congealed matrix with drug 
The spray congealed microparticles should have reasonable 
mechanical properties, to withstand blending with appropriate excipients, 
before compaction to form tablets. Direct compression is the simplest and 
most cost effective way to manufacture a tablet dosage form (Gohel and 
Jogani, 2005).  
The mechanical properties of a formulation can influence common 
pharmaceutical unit operations, such as granulation, compression, milling, and 
mixing (He, 2009). The typical mechanical strength test using three point 
bending test or diametral compression test was not feasible for micron-sized 
spray congealed microparticles. Additionally, the three point bending test is a 
qualitative test and results of the testing method are sensitive to the specimen 
geometry, loading of the specimen and strain rate used (Bose, 2014). Hence, 
particle size of the microparticles from the milling of the solid dispersions was 
used to reflect the mechanical strength of the congealed matrix.  
 
1. Effect of HPMC concentration  
Addition of HPMC to MNZ-loaded PEG matrix decreased the size of 
the microparticles produced (Figure 27). Regardless of the grades, the median 



































































































































































Figure 27. Median particle size and size span of MNZ-loaded PEG 
microparticles produced with various HPMC concentrations: (a) E-series; (b) 
F-series; (c) K-series and (d) Methocel vLV. 
Note: Error bars are omitted to avoid cluttering of the graphs. 
 
around 200-300 µm. As the concentration of HPMC was increased, the 
particle size generally decreased. The extent of change in particle size 
decreased with increasing HPMC concentration. The molten mixture consisted 
of a dispersion of HPMC and MNZ particles in PEG. Not all the MNZ added 
dissolved in the molten PEG. As the concentration of MNZ was kept constant, 
any changes observed would be largely attributed to the different HPMC 
concentrations. The presence of solid particles would affect the continuity and 
thus the strength of the matrix when the molten PEG solidified. PEG is a weak 
material from the point of view of strength, but it is ductile and plastic in 
behaviour (Al-Nasassrah et al., 1998). During milling, the weak PEG matrix 
would fracture into smaller particles when the yield pressure was reached 
(Alderborn and Nystrom, 1995). The smaller particle size could be attributed 
to the greater ease of breaking down a weaker matrix. However, at higher 


















































suggests the existence of a critical HPMC concentration, above which there 
was no effect on the particle size. For formulations that employed HPMC of 
the E-series and F-series, the critical HPMC concentration was 15 % whereas 
it was 10 % for the K-series and 20 % for the Methocel vLV series.     
The size span was found to increase significantly from 1.6 to above 2 
(p < 0.05) irrespective of the grade of HPMC added. The size span however 
remained relatively constant despite further increase in the HPMC 
concentration. This shows that the addition of HPMC increased the 
polydispersity of the microparticles. As discussed previously, the presence of 
HPMC and MNZ particles reduced the strength of the PEG matrix. As such, 
collision of the microparticles with one another and with the equipment 
surfaces during milling might cause further breakdown of the microparticles, 
leading to higher polydispersity of the microparticles collected.   
 
2. Effect of viscosity 
The viscosity of the molten mixtures could potentially have an effect 
on the mechanical strength of the congealed matrix. According to Figure 27d, 
the median particle size decreased by about 230 µm when 5 % Methocel vLV 
was added. Addition of the other HPMC grades of 5 % concentration resulted 
in significantly greater size reduction of 280 – 330 µm (p < 0.05). Since the 
different HPMC grades affected the viscosity of the molten mixtures to 
different extents, it would be of interest to determine the influence of viscosity 
on the size and size distribution of the microparticles produced. The effects of 
different grades and concentrations of HPMC on the viscosity of MNZ-loaded 
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molten PEG were first investigated. Figure 28 shows the effect of HPMC 






















































































Figure 28. Viscosity of molten PEG mixtures comprising 20 % MNZ and 
various HPMC concentrations of different grades: (a) E-series; (b) F-series; (c) 
K-series and (d) Methocel vLV, at 80 °C. 
 
As mentioned previously, any change observed would be largely 
attributed to the different HPMC concentrations since the concentration of 
MNZ was kept constant. Addition of HPMC at low concentrations (generally 
below 15 %) did not cause any appreciable change in the viscosity of the 
molten mixture (p > 0.05). Some HPMC might have dissolved in the molten 
PEG but the dissolved, as well as the undissolved HPMC did not have any 
significant effect on the viscosity. However, at higher HPMC concentrations, a 
small increase in HPMC concentration resulted in a marked increase in 
viscosity (p < 0.05). Viscosities of certain formulations were not determined 
due to the inability of the rheometer to measure molten mixtures with very 
high viscosities. The viscosity was affected to different extents by the different 
HPMC grades. It was increased markedly at HPMC concentration above 15 % 
for Methocel vLV and the E- and F-series, but above 10% for the K-series. At 
low concentrations of HPMC, the particles were few and far apart from one 
another, allowing the fluid (molten PEG) to move freely between them. At the 


























critical concentration of 10 to 15 %, the HPMC particles began to affect fluid 
flow. With increasing concentration of HPMC, the propensity of HPMC 
particles to form loose aggregates or flocs would increase. These flocs posed a 
resistance to flow (Genovese, 2012; Saeed et al., 2009; Santamarı´a-Holek and 
Mendoza, 2010). 
To investigate the effect of viscosity on the mechanical strength of the 
congealed matrix, a scatter plot of viscosity against particle size and size 
distribution of all the formulations was constructed (Figure 29).  
 













































Figure 29. Viscosity of the molten mixture at 80 ºC and resultant median 
particle size and size span obtained from milling of solid dispersion. 
 
The median particle size was reduced from 530 µm to around 200 µm 
following a slight increase in the viscosity of the molten mixtures from 0.77 to 
2.08 Pa.s. In addition, the median particle size remained relatively constant at 
approximately 200 µm despite further increase in viscosity. The size span of 
the microparticles, however, showed an opposite trend. It increased slightly 
and then remained relatively constant within the range of 2 to 3.5. Thus, a 
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slight increase in viscosity affected the mechanical strength of the congealed 
matrix but the effect was insignificant when viscosity was increased further. 
 
C. Effect of HPMC on MNZ crystallinity at high drug concentration 
Compared to the corresponding physical mixture, the microparticles 
showed lower drug crystallinity. The percentage reduction in drug crystallinity 






























































































































































Figure 30. Percentage reduction in drug crystallinity and viscosity of molten 
mixtures comprising 20 % MNZ and various HPMC concentrations: (a) E-
series; (b) F-series; (c) K-series and (d) Methocel vLV. 
 
Upon rapid cooling, the dissolved MNZ having little time to rearrange 
themselves would largely orientate in a haphazard manner. Thus, most of the 
MNZ would recrystallise out as amorphous particles or remained as a 
molecularly dispersion, leading to a reduction in the MNZ crystallinity. Those 
formulations with HPMC had a slightly higher reduction of 76.25 % 
regardless of the HPMC grade and concentration used. During the 























































































































































MNZ molecules to deposit on the surface of the particle. However, as HPMC 
consisted of fibrous particles of variable geometry, the MNZ molecules would 
deposit and orientate in a random and haphazard manner, leading to formation 
of amorphous clusters. The MNZ molecules could also remain as a molecular 
dispersion through hydrogen bonding with HPMC and PEG (to be discussed 
in later sections). The combined effects of rapid cooling and HPMC resulted 
in greater reduction in MNZ crystallinity. The addition of 5 % HPMC into the 
molten mixture did not cause any appreciable change in the viscosity. At 20 to 
25 % HPMC, the viscosity increased markedly but the reduction in drug 
crystallinity did not increase further. This suggests that the change in viscosity 
of the molten mixture was not the primary factor affecting drug crystallinity. 
The reduction in drug crystallinity was attributed to the physical presence of 
HPMC. 
 
D. Summary for Part IV 
The microparticles investigated were produced by milling of the solid 
dispersions. The purpose of this study was to investigate the effect of HPMC 
on the mechanical strength of the congealed matrix and the crystallinity of 
MNZ in the matrix. HPMC altered the properties of PEG matrix and the drug, 
MNZ, when used as an additive. The addition of HPMC decreased the median 
microparticle size obtained, indicating a decrease in mechanical strength of the 
matrix. HPMC increased the size span of the microparticles slightly. The size 
span remained relatively constant despite further addition of HPMC. Low 
HPMC concentration had little effect on the formulation viscosity. A sharp 
rise in viscosity was however produced at HPMC concentrations greater than 
103 
 
10 %. The reduction in drug crystallinity was due to the physical presence of 
HPMC and not the viscosity of the molten mixture.  
 
Part V. Impact of HPMC on spray congealed PEG microparticles 
with/without drug 
 To investigate the impact of HPMC in spray congealed microparticles, 
the K-series was selected as it has the largest number of different grades. The 
composition of the different formulations of molten mixtures and 
microparticles is shown in Table 8. Some formulations were prepared with 10 
% MNZ to investigate the solid state properties of the drug after spray 
congealing. 
 
A. Total yield and useful yield 
The total yield of the spray congealing process ranged from 58.0 to 
71.0 % while the useful yield ranged from 42.6 to 58.4 % (Figure 31). The 
loss in total yield was attributed to some molten material remaining in the 
tubing and atomizer as well as microparticles adhering to the walls of the 
cooling chamber.  
The total yield of the control (PEG only) was generally lower than that 
of formulations with HPMC. Molten PEG is tacky, and the addition of HPMC 
reduces the tackiness of the molten mixture (Lo and Law, 1996). Hence, less 
molten mixture was lost to the feeding tubes, resulting in a higher total yield. 
The useful yield of the control (PEG only) was observed to be the lowest 




Table 8. Composition of molten mixtures and morphology of the spray congealed microparticles produced. 
Formulations PEG (%, w/w) 
HPMC grades (%, w/w) 
Aspect ratio Size span 
K100 LV K4M K15M K100M 
1 (control) 100 – – – – 1.03 ± 0.03 1.83 ± 0.01 
2 95 5 – – – 1.05 ± 0.02 1.93 ± 0.06 
3 90 10 – – – 1.03 ± 0.02 1.89 ± 0.14 
4 85 15 – – – 1.04 ± 0.04 1.85 ± 0.01 
5 95 – 5 – – 1.02 ± 0.01 1.67 ± 0.02 
6 90 – 10 – – 1.03 ± 0.03 1.72 ± 0.07 
7 85 – 15 – – 1.04 ± 0.04 1.67 ± 0.04 
8 95 – – 5 – 1.03 ± 0.01 1.73 ± 0.01 
9 90 – – 10 – 1.01 ± 0.01 1.66 ± 0.04 
10 85 – – 15 – 1.02 ± 0.01 1.67 ± 0.02 
11 95 – – – 5 1.05 ± 0.04 1.67 ± 0.13 
12 90 – – – 10 1.01 ± 0.01 1.62 ± 0.04 










Figure 31. Total and useful yields of microparticles from different 
formulations.  
 
the atomizing air, thereby resulting in a larger fraction of smaller 
microparticles. These smaller microparticles were collected as fines, resulting 
in PEG having the lowest useful yield.  
The total and useful yields increased when 5 % of HPMC was added, 
regardless of the HPMC grades. When the concentration of HPMC was further 
increased, the total yield decreased for all HPMC grades. However, the useful 
yield was found to be the highest for 10 % HPMC concentration. The viscosity 
of the molten mixture was previously found to increase as HPMC 
concentration increased. The more viscous molten mixture would require a 
greater amount of shear to form droplets. Insufficient shear force would result 
in bigger droplets, which may not solidify adequately in time before impacting 
on the chamber wall. This would result in adherence of the material to the wall 

































































































the useful yield generally increased when the HPMC concentration was raised 
from 5 to 10 %. Microparticle size increased with the viscosity of the molten 
mixture (discussed in later sections). Hence, more microparticles were 
collected as useful fraction and less fines were formed at HPMC concentration 
of 10 %. Overall, the results suggest that HPMC has the potential to increase 
the useful yield of spray congealing when used as an additive at low 
concentrations. The HPMC concentration of 10 % was found to be optimal as 
it resulted in the highest useful yield. 
 
B. Characterisation of spray congealed microparticles 
1. Morphology of microparticles 
All the microparticles were relatively free-flowing and off-white in 
colour (Figure 32). Generally, spray congealed PEG microparticles with 
HPMC resulted in discrete, smooth and spherical microparticles, with an 
aspect ratio ranging from 1.01 to 1.05 (Table 8).  
 
 
Figure 32. Photomicrographs of microparticles composed of (a) PEG only; 
PEG with 15 % HPMC (b) K100 LV, (c) K4M, (d) K15M and (e) K100M; (f) 





No significant difference in appearance was observed for 
microparticles with and without HPMC. The addition of MNZ also did not 
affect the morphology of the microparticles significantly. Under polarised 
light, all the microparticles appeared to have a glowing crystalline surface, 
suggesting that the matrix of the microparticles comprised crystalline PEG. 
 
2. Size and size distribution of microparticles 
The influence of molten mixture viscosity on the microparticle size is 
presented in Figure 33. For the same HPMC grade, the microparticle size 
increased with increasing viscosity of the molten mixture. This trend is in 
good agreement with the findings from other studies (Albertini et al., 2008; 
Juslin et al., 1995; Maschke et al., 2007).  
 
 
Figure 33. Median particle size and viscosities of various formulations. 
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The relationship between microparticle size and molten mixture 
viscosity is non-linear. In comparison with the control (PEG only 
microparticles), microparticle size was observed to increase significantly (p < 
0.001) with a slight increase in the viscosity corresponding to 5 % HPMC. 
However, when the viscosity of the molten mixture increased markedly with 
the addition of 15 % HPMC, microparticle size did not increase 
proportionally. Upon closer examination, similar microparticle sizes were 
found (p > 0.05) for 15 % K4M, K15M and K100M despite their different 
molten mixture viscosities. Higher viscosity molten mixtures resulted in larger 
droplet sizes, which might not have solidified in time before impacting the 
chamber wall. These semi-solid microparticles would adhere to the wall. As a 
result, the microparticles collected from the product collection vessel would be 
similar in size and aptly accounted for the similar median particle size for 
K4M, K15M and K100M at concentration of 15 %. K100 LV resulted in 
significantly lower viscosity than the other three grades at all HPMC 
concentrations (p < 0.05). However, K100 LV produced consistently larger 
microparticles, deviating from the expected trend. It is possible that the low 
viscosity of the molten feed enabled better flow to the atomiser, resulting in 
bigger atomised droplets as the available feed was insufficiently sheared by 
the atomising air. Upon cooling, larger microparticles were formed.  
Further analysis was carried out to investigate whether viscosity of the 
molten mixture was a good predictor of microparticle size. Figure 34 shows 
the scatter plot of viscosities of all formulations and their particle sizes. A 
correlation between the viscosity of the molten mixtures and the microparticle 
size was observed when molten mixtures containing HPMC K100 LV were 
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excluded (r = 0.845). The microparticle size increased from 68.6 to 154 μm 
with increasing viscosity of molten mixture before reaching a plateau at the 
viscosity of 0.897 Pa.s. This implies that microparticle size increased with 
viscosity of the formulation up to a certain limit. It further substantiated the 
earlier observation of maximum microparticle size achievable in the cooled 
chamber.   
 
 
Figure 34. Scatter plot of microparticle size with increasing viscosity. 
 
The addition of different grades of HPMC did not greatly impact the 
size span. The size span of the spray congealed microparticles was found to be 
between 1.62 and 1.93 (Table 8). The K100 LV grade generally resulted in 
microparticles with greater size span compared to the other three HPMC 
grades throughout all the concentrations used, indicating a broader size 
distribution. Overall, microparticles of K100 LV produced are larger with a 
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broader size distribution. The addition of HPMC was not particularly useful in 
reducing the polydispersity of the microparticles produced. 
 
3. Solid state properties of MNZ in the spray congealed microparticles 
In the previous study (Part IV), the presence of HPMC was found to 
reduce the crystallinity of MNZ in solid dispersions. Hence, further 
investigation was carried out to evaluate the impact of HPMC on MNZ 
crystallinity in spray congealed microparticles. HPMC K15M was selected for 
this study as it gave a good useful yield of microparticles after spray 
congealing which would enable further analysis. Table 9 shows the 
formulations of the spray congealed microparticles prepared with drug.  
 
Table 9. Composition of different spray congealed microparticles with drug. 






P 100 0 0 
PM 90 10 0 
PMH5 85 10 5 
PMH10 80 10 10 
PMH15 75 10 15 
 
The drug crystallinity and possible solid state structure of MNZ present 
in the microparticles were investigated using a combination of XRD, DSC, 
Raman spectroscopy and FT-IR spectroscopy. X-ray diffraction spectra of 
single components showed the crystalline nature of PEG and MNZ, with 
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major peaks at 19.3° and 23.4° for PEG and major peaks at 12.5°, 14°, 24.8°, 
29.4° and 33.3° for MNZ (Figure 35a). HPMC had no distinct peaks which 




Figure 35. X-ray diffraction spectra of (a) single components and (b) spray 
congealed microparticles and corresponding physical mixtures.  
 



























































Figure 35b shows the XRD spectra of the freshly spray congealed 
microparticles and their corresponding physical mixtures. The XRD spectrum 
of P microparticles was similar to that of the single component (P*), indicating 
that any effect of the spray congealing process on PEG was transitional. Upon 
melting, PEG molecules were less organised but upon solidification when the 
temperature was lowered, the molecules rearranged themselves to form helices 
that aligned in an orderly fashion, indicating that PEG crystallized easily 
(Dhirendra et al., 2009). The PM microparticles showed lower MNZ peak 
intensity in comparison with the corresponding physical mixture (PM*). There 
were no new peaks observed, indicating the absence of MNZ polymorphic 
transition. This highlights the ability of the spray congealing process in 
reducing the drug crystallinity, thereby potentially enhancing dissolution of 
the drug. The MNZ peak intensity at 12.5° for PMH5 (417), PMH10 (458) and 
PMH15 (594) microparticles was significantly lower (p < 0.05) than that of the 
PM (901) microparticles. Compared to the corresponding physical mixture, 
the percentage reduction in MNZ crystallinity in microparticles of PM, PMH5, 
PMH10 and PMH15 was 75.3 %, 85.0 % and 83.5 % and 78.6 % respectively. 
Collectively, the results showed that the spray congealing process reduced the 
MNZ crystallinity to a much greater extent than HPMC. The reduction in 
MNZ crystallinity by HPMC was dependent on the concentration of HPMC. 
The ability of HPMC to reduce the crystallinity of another drug, felodipine, 
has been reported (Konno and Taylor, 2006).  
The process of spray congealing resulted in a slightly greater reduction 
in MNZ crystallinity of PM microparticles (75.3 %) compared to the melting 
method (73.3 %, Figure 30). This demonstrates that spray congealing is 
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slightly more effective in altering the crystallinity of the drug. In both 
processes, addition of HPMC reduced MNZ crystallinity further. Averaged 
reduction in MNZ crystallinity for all grades and concentration of HPMC used 
was 76.3 % for microparticles produced with the melting method (Figure 30) 
and 82.4 % for spray congealed microparticles. Hence, crystallinity of a drug 
is dependent on the process method and formulation employed. 
The XRD data were further supported by the results of the DSC 
studies. Figure 36a shows the DSC curves of the single components. PEG and 
MNZ showed a strong endothermic peak at about 60 °C and about 165 °C 
respectively. HPMC showed a broad peak which reflected its amorphous 
nature. The physical mixtures and microparticles consisted of 10 % MNZ. The 
physical mixtures PM* and PMH5*, did not show any noticeable MNZ 
endothermic peak upon melting (Figure 36b). This could be attributed to the 
drug dissolving into PEG when the sample was heated. However, very small 
MNZ endothermic peaks were observed for the physical mixtures PMH10* and 
PMH15*, with enthalpy of 4.46 and 4.60 J/g respectively. The higher 
concentration of HPMC present prevented complete dissolution of the drug in 
PEG. The PMH10 and PMH15 microparticles also showed very small MNZ 
endothermic peaks, but their enthalpy of 3.21 and 3.64 J/g respectively, were 
significant lower (p < 0.05). This significant reduction in enthalpy of fusion in 
the microparticles compared to the corresponding physical mixture indicated 























































































Figure 36. DSC curves of the (a) single components and (b) spray congealed 
microparticles and corresponding physical mixtures.  
 
The drug can be present as small crystalline particulates, amorphous 
particulates or molecularly dispersed within the PEG matrix (Chiou and 
Riegelman, 1971; Craig, 2002). Previously, the reduction in drug crystallinity 
was attributed to the drug existing as amorphous particles. Therefore, in this 
study, Raman spectroscopy and FT-IR spectroscopy were used to further 





as amorphous particles. Drug-matrix interactions, such as hydrogen bonding, 
can be used to differentiate if the drug exist predominantly as molecular 
dispersion compared to amorphous particles as these interactions are critical 
for drugs to remain molecularly dispersed (Dhirendra et al., 2009). Both 
Raman spectroscopy and FT-IR spectroscopy will be able to evaluate possible 
interactions of MNZ with PEG or HPMC. The homogeneity of the drug 
distribution in the microparticles will also be investigated by Raman 
spectroscopy.  
The Raman spectra of the single components are shown in Figure 37a-
c while those of PM, PMH5, PMH10 and PMH15 microparticles are shown in 
Figure 37d. The characteristic peak of the NO2 (N–O stretching) of MNZ at 
1528 cm
−1
 was observed in the spectra of microparticles with MNZ, indicating 
the presence of MNZ on the microparticle surface. This suggests that the drug 
was not totally embedded in the core of the microparticles when spray 
congealed and that concentration of HPMC up to 15 % was not sufficient to 
fully coat the microparticle surface. 
Materials of crystalline structure are characterised by distinct and well-
defined peaks in the Raman spectrum. The presence of drug peaks in the XRD 
and Raman spectra and endothermic peak in DSC curves indicate the presence 
of crystalline MNZ in the microparticles. If the percentage of the drug is high, 
it will form small crystals rather than remain molecularly dispersed within the 
microparticles (Leuner and Dressman, 2000). In light of this, solubility of 
MNZ in PEG was determined and found to be 10.67 % (w/w) at 80 °C. The 
percentage weight of the drug with respect to PEG in PM (11.11 %), PMH5 

















































































































































































































































































































































Figure 37. Raman spectra of (a) PEG, (b) MNZ, (c) HPMC, (d) PM, PMH5, PMH10 and PMH15 microparticles. 


















































































































solubility limit. This aptly explains the presence of small crystals in those 
microparticles, accounting for peaks in the Raman spectra. Taking into 
account that there was a decrease in drug crystallinity, the remaining portion 
of MNZ within the microparticles could exist in the amorphous form and/or 
was dispersed molecularly. 
Characteristic bands of MNZ, PEG and HPMC in Raman and FT-IR 
spectra are listed in Table 10. Raman spectra of MNZ (Figure 37b) and HPMC 
(Figure 37c) exhibit a broad peak at 3441 cm
−1
 and 3220 cm
−1
 respectively, 
indicative of intermolecular hydrogen bonding of the OH group. The spectra 
of PM, PMH5, PMH10 and PMH15 (Figure 37d) showed a shift of the NO2 (N–
O stretching) and OH stretching to a lower wavenumber, indicating the 
presence of hydrogen bonding between MNZ, PEG and HPMC. The shift in 
the OH stretching was greater for PMH5, PMH10 and PMH15
 
compared to PM, 
indicating a larger extent of hydrogen bonding when HPMC was added.  
FT-IR spectra of MNZ, PEG and HPMC are shown in Figure 38a-c. 
Figure 38d-e demonstrated a slight broadening of the OH stretching of MNZ 
in the microparticles compared to the physical mixtures, indicative of the 
formation of hydrogen bonds between MNZ, PEG and HPMC. The presence 
of MNZ-PEG interaction in PM indicates that the drug exists as a molecular 
dispersion rather than as amorphous particles. A greater interaction when 
HPMC was added suggests that formation of hydrogen bonds between HPMC 
and MNZ prevented the recrystallisation of the molecularly dispersed drug and 









Characteristic bands Reference 
PEG OH group stretching at 3600 to 3200 cm
−1
  
R–CH2 stretching at 3000 to 2850 cm
−1
 
(Mansur et al., 
2004) 
CH2 twisting at 1242 cm
−1
 




C–O–C stretching at 1116 cm−1  










MNZ OH stretching at 3220 cm
−1
 
C=CH stretching at 3101 cm
−1
 
NO2 (N–O stretching) at 1528 cm
−1
 
C–OH, C–O stretching at 1074 cm−1  





HPMC OH stretching at 3441 cm
−1
  
C–H stretching at 3000 to 2800 cm−1  
















Figure 38. FT-IR spectra of: (a) PEG, (b) MNZ, (c) HPMC, (d) physical 
mixtures PM*, PMH5*, PMH10* and PMH15* and (e) microparticles PM, 
PMH5, PMH10 and PMH15.   
Note: All the physical mixtures and microparticles had similar FT-IR spectra. 
Hence, only one spectrum of the physical mixture and one of the 
microparticles are shown to avoid duplication. 
 
4. Drug content and encapsulation efficiency 
All the formulations contained 10 % MNZ but the drug contents of the 
various microparticles produced were not similar. The drug content and 
encapsulation efficiency of the microparticles are summarised in Table 11. 
Formulation PM without HPMC had the highest content of MNZ, followed by 





ranged from 73.0 to 91.9 %. Formulations containing HPMC (PMH5, PMH10 
and PMH15) demonstrated a good, albeit lower, encapsulation efficiency of the 
drug. Without the addition of HPMC in the formulation, molten PEG only 
encapsulated the drug particles before solidification, resulting in higher 
encapsulation efficiency. Addition of HPMC to the formulation reduced the 
proportion of PEG and thus reduced the encapsulation efficiency. When a high 
concentration of 15 % w/w HPMC was used (PMH15), more HPMC and less 
MNZ particles were encapsulated, resulting in reduced encapsulation 
efficiency. 
 
Table 11. Drug content and encapsulation efficiency of various formulations. 
Formulation Drug content (%, w/w) Encapsulation 
efficiency (%) 
PM 9.19 ± 0.10 91.92 ± 0.97 
PMH5 8.28 ± 0.17 82.78 ± 1.73 
PMH10 8.62 ± 0.34 86.18 ± 3.41 
PMH15 7.30 ± 0.27 72.95 ± 2.73 
 
C. Drug dissolution of MNZ 
The different batches of microparticles and pure MNZ were sieved to 
obtain samples with similar particle size range (125 to 250 µm) for dissolution 
studies at pH 7.4. The dissolution of the pure MNZ was complete at 15 min 
(Figure 39a). Even though MNZ is poorly water soluble, the particles 
dissolved rapidly due to the small particle size of the drug and the sink 
condition of the dissolution medium. The dissolution profiles were plotted as a 
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function of log time to better differentiate the early phase of dissolution 
(Figure 39b). From this plot, it was more clearly seen that the PM, PMH5 and 
PMH10 microparticles showed comparable dissolution rates which were 
greater than that of the pure MNZ. This shows that spray congealing is able to 
enhance the dissolution of MNZ through reduction in MNZ crystallinity. 
HPMC is commonly used in preparations to modify drug release. Addition of 
5 or 10 % w/w HPMC (PMH5 and PMH10) further reduced the MNZ 
crystallinity by 3 to 10 % but this did not further enhance the release of MNZ.  




















































Figure 39. Dissolution profiles of various microparticles at pH 7.4: (a) as a 






Interestingly, PMH15 was found to have a slower dissolution than PM, 
PMH5 and PMH10. It was possible that the concentration of HPMC in PMH15 
was sufficient to form a layer of gel that acted as a barrier to drug release. 
Burst effect of drug was observed for all microparticles, indicating drug 
particles were present on the outer layer of the microparticle, which dissolved 
rapidly upon contact with the dissolution medium. This was supported by the 
presence of MNZ on the surface of the microparticles as indicated by Raman 
spectroscopy and the incomplete coat formation by HPMC. Nevertheless, 
HPMC concentration of up to 10 % resulted in faster drug dissolution than 15 
% HPMC.  
 
D. Summary for Part V 
HPMC was successfully incorporated into spray congealed PEG-MNZ 
microparticles where it exerted a significant effect on the properties of the 
drug and characteristics of the microparticles produced. Spherical and free 
flowing microparticles with useful yield ranging from 42.6 to 58.4 % were 
obtained. An increase in concentration of HPMC increased the viscosity of the 
molten mixture and size of the resultant microparticles, with little effect on 
their polydispersity. The microparticles produced had good encapsulation 
efficiency of MNZ. Furthermore, microparticles containing HPMC had 
decreased drug crystallinity. The MNZ within the microparticles existed 
mostly as a molecular dispersion besides as amorphous particles. Rapid 
dissolution of the MNZ from the microparticles without, or with 5 % or 10 % 
HPMC was attributed to the reduction in drug crystallinity due to spray 
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congealing. However, dissolution of microparticles with 15 % HPMC was 
retarded due to the formation of a diffusion barrier by the HPMC. 
 
Part VI. Swelling effect of different grades and concentrations of HMPC 
The dissolution rate of MNZ from microparticles could be partly 
affected by matrix swelling. Therefore, in this part of the study, the effects of 
different HPMC grades and concentrations on the swelling of microparticles 
were investigated. An amorphous and more lipophilic drug, rifampicin (RIF), 
was selected to study swelling effect of matrix on drug dissolution. Being 
amorphous, there was no confounding effect of drug crystallinity and a more 
lipophilic drug allows the impact of swelling on dissolution to be more 
prominent. Three size fractions of microparticles (<125 µm, 125 to 250 µm 
and > 250 µm) were used in this study. 
The extent of swelling and rate of erosion of the microparticles were 
determined as shown in Figure 40. Upon contact with water, HPMC particles 
on the outer core was hydrated and swelled. If the concentration of HPMC was 
sufficient, a gel layer would form and act as a barrier to drug diffusion. 
Erosion would simultaneously occur at this stage as PEG is water soluble. 
However, the erosion rate would be slower than the swelling rate. As water 
continued to penetrate into the microparticle, HPMC particles in the inner core 
swelled, leading to an increase in microparticle size. Eventually, the outer core 




Figure 40. Microparticles with (a) PEG only, (b) PEG and low concentration 
of HPMC and (c) PEG and high concentration of HPMC. Images shown are as 
follows: (1) before and (2) after contact with water, (3) swelling to its 
maximum extent and (4) during erosion. 
 
A. Extent of swelling 
Swelling analysis of the microparticle size fraction 125 to 250 µm was 
first conducted. Only K100M showed an increase in swelling when 5 % 
HPMC concentration was added. The extent of swelling of microparticle 
decreased for HPMC grades K100 LV, K4M, K15M and K100M as HPMC 
concentration increased from 5 to 15 % (Table 12). This phenomenon can be 
explained by the percolation theory, which states that below the critical 
concentration (percolation threshold, pc), particles form isolated clusters; at the 
pc, an ‘infinite cluster’ or complete network is formed (Leuenberger, 1999). At 
5 % HPMC, the number of HPMC particles was below the percolation 
threshold. The individual HPMC particles hydrated and swelled to form 








Swelling extent of microparticles (%) 
K100 LV K4M K15M K100M 
0 25.8 25.8 25.8 25.8 
5 25.6 23.4 22.9 28.8 
10 22.8 22.2 22.3 25.4 
15 21.9 20.3 21.5 24.7 
 
more clusters formed, accompanied by a greater propensity to merge and 
posed a greater resistance to water penetration. This aptly accounted for the 
decreasing swelling extent with increasing HPMC concentration. Higher 
HPMC concentrations were needed to form a complete barrier to strongly 
impede water penetration and prevent swelling. A complete barrier would be 
formed when the HPMC concentration reached the percolation threshold. 
Beyond this threshold, increase in HPMC concentration would have minimal 
effect on swelling and the swelling extent would reach a constant. For all the 4 
grades of HPMC, the swelling extent continued to decrease with increasing 
HPMC concentration. It could therefore be inferred that 15 % HPMC 
concentration was still below pc. In the case of K100M, the swelling extent 
appeared to approach constant at about 15 % HPMC. This concentration is 
probably close to the pc which corresponds to the formation of an ‘infinite 
cluster’ and complete barrier to water penetration. For K100 LV, K4M and 
K15M, the pc is likely much higher than 15 %. K100 LV, K4M and K15M had 
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comparable median particle size which was significantly larger than that of 
K100M (Figure 17a). HPMC of smaller particle size had lower pc value. The 
increase in swelling extent when 5 % K100M was added could be attributed to 
the greater extent of swelling shown by the isolated and smaller K100M 
particles. 
To enable a better visual comparison between the swelling extents of 
all HPMC grades for all microparticle size fractions, surface plots were 
constructed (Figure 41a). Regardless of the HPMC grades used, spray 
congealed microparticles of size fraction 125 to 250 µm generally 
demonstrated the greatest extent of swelling (20 to 29 %; obtained from 
surface plots) compared to the other size fractions of < 125 µm (13 to 24 %; 
obtained from surface plots) and > 250 µm (14 to 18 %; obtained from surface 
plots) at each corresponding HPMC concentration. Swelling extent was not 
directly related to microparticle size. By virtue of their larger particle size, 
microparticles of size fraction 125 to 250 µm could accommodate a larger 
number of HPMC particles compared to microparticles of size fraction < 125 
µm, and have a greater tendency to swell more. On the other hand, 
microparticles of size fraction > 250 µm exhibited a lower extent of swelling 
due to limited water penetration into the microparticle for swelling to occur. 
Microparticles of the smallest size fraction (<125 µm) had increased 
swelling when 5 % HPMC was added regardless of the grade. Water has to 
penetrate the microparticle for swelling to occur. For this fraction of relatively 
small microparticles, water penetration was relatively fast, resulting in rapid 
hydration and subsequently swelling of HPMC particles within the 










microparticles containing K100 LV swelled more (from 17.3 to 24.2 %; 
obtained from surface plot) while those containing K100M decreased in 
swelling extent (from 18.4 to 12.9 %; obtained from surface plot). The 
swelling extent of microparticles containing K4M and K15M remained 
constant. A greater capacity of swelling does not necessarily equate to barrier 
formation. For microparticles containing K100 LV, the continual increase in 
extent of swelling with increasing HPMC concentration suggested that the 
capacity to swell was greater than the capacity to form a barrier. However, 
K100M had a greater tendency to form a barrier as seen in the decrease in 
swelling extent when concentration increased above 5 %. The smaller K100M 
particles could form a more uniform barrier upon swelling compared to larger 
HPMC particles. For K4M and K15M, the swelling extent was constant even 
with increasing HPMC concentration suggesting that the pc was reached at 5 
%. 
With larger size fractions (> 250 µm), water penetration was relatively 
slower due to the smaller surface area to volume ratio. The PEG molecules 
and HPMC particles on the outer core hydrated faster than those in the inner 
core. Microparticles with HPMC particles swelled appreciably more than 
those without HPMC (Figure 41a). As HPMC concentration increased from 5 
to 15 %, microparticles with K100 LV, K4M and K15M had relatively similar 
extent of swelling (16.3 to 17.4 %; obtained from surface plots) while that of 
K100M continued to increase (14.0 to 18.2 %). Hence, the pc was reached at 
about 5 % for K100 LV, K4M and K15M but not K100M. For K100M, the 
barrier was not formed even at 15 % concentration, thus the swelling extent 
continually increased. One possible reason could be related to the particle size 
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of the different HPMC grades. As mentioned previously, the median particle 
size of HPMC K100M was significantly smaller (p < 0.05) than that of K100 
LV, K4M and K15M. For microparticle size fraction of > 250 µm, the 
swelling of smaller HPMC particles was inadequate to form a complete gel 
layer. Larger HPMC particles (K100 LV, K4M and K15M) were more 
suitable for this purpose. 
The extent of microparticle swelling is dependent on the HPMC grade, 
number of HPMC particles present within the microparticle and the particle 
size of HPMC. K100 LV caused greater swelling of microparticles compared 
to the other grades while HPMC K100M had a greater tendency to form a 
more uniform barrier. A barrier would only be completely formed upon 
reaching percolation threshold where the HPMC particles swelled adequately 
and formed a continuous gel layer surrounding the microparticle.  
 
B. Rate of erosion 
Among the different size fractions, microparticles in the size fraction 
of 125 to 250 µm generally showed the slowest rate of erosion regardless of 
the HPMC grade employed. The rates of erosion of these microparticles 
consisting of different HPMC grades are shown in Table 13. The addition of 5 
% HPMC concentration slowed the rate of microparticle erosion regardless of 
the HPMC grade used. No particular trends were observed with increasing 
HPMC concentration. Surface plots were constructed to enable better data 
visualisation (Figure 41b). Microparticles of size fraction < 125 µm containing 
10 % HPMC and those > 250 µm without HPMC consistently demonstrated 
the fastest rate of erosion for all four HPMC grades. Microparticles > 250 µm 
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without HPMC eroded in a shorter time due to the presence of more micro-
fissures in larger microparticles compared to smaller ones.  
 




Rate of erosion of microparticles (µm2/s) 
K100 LV K4M K15M K100M 
0 1.73 1.73 1.73 1.73 
5 1.54 1.64 1.69 1.57 
10 1.63 1.51 1.50 1.64 
15 1.61 1.51 1.62 1.44 
 
For microparticle of size fraction 125 to 250 µm, the HPMC 
concentration which resulted in the slowest rate of erosion differed between 
the grades; K100 LV at 5 %, K4M at 10 to 15 %, K15M at 10 % and K100M 
at 15 %. One of the factors that affected the rate of microparticle erosion is the 
formation of barrier by HPMC. As the HPMC concentration increased, the 
barrier network increased in tandem, resulting in decreased rate of 
microparticle erosion. 
For microparticles of size fraction > 250 µm, those consisting of K100 
LV, K4M and K15M had slower rate of erosion at HPMC concentration 
greater than 5 % (percolation threshold). HPMC particles in close proximity 
gelled upon contact with water, forming a complete barrier which retarded 
microparticle erosion. Barrier formation provided resistance to erosion. At 5 
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%, the percolation threshold for K100M was not yet reached. Rate of erosion 
of K100M was faster than the other three HPMC grades. Microparticles 
without a sufficient number of HPMC particles would form an 
incomplete/partial barrier as the percolation threshold was not reached. 
Microparticles without complete barrier formation had a faster rate of erosion 
because the PEG particles would dissolve upon contact with water, leaving 
micro-cavities which would facilitate water penetration and dissolution of 
PEG.  
There was a deviation from the above trend for microparticles of size 
fraction < 125 µm containing K100M. As previously discussed, barrier 
formation had occurred in these microparticles. However, these microparticles 
had a relatively fast rate of erosion (Figure 41b). This suggested that barrier 
formation was not the sole determinant of microparticle erosion rate. The 
HPMC grades, which vary in molecular weight and propensity for chain 
entanglement, also had an effect on the rate of erosion. It had been reported 
that greater entanglement of the polymer chains would not only reduce the rate 
of erosion, but also reduced the rate of water penetration and subsequent 
hydration of other polymer molecules (Chaibva et al., 2010). Therefore, the 
rate of erosion depended on the formation of the barrier and the HPMC grade 
used. Correlation analysis was carried out between the extent of swelling and 
rate of erosion but no direct correlation between the two variables was found. 
An increase in extent of microparticle swelling did not necessarily result in a 





C. Swelling effect on dissolution of rifampicin 
Formulation with 10 % K15M was selected to be spray congealed with 
RIF as it exhibited barrier formation and a relatively slower rate of erosion 
compared to other formulations. The formulation with 10 % K100 LV also 
exhibited barrier formation and was selected to evaluate the impact of HPMC 
grade on drug release. Formulation composed of RIF without HPMC (RIF-
PEG) were also spray congealed for comparative study. Microparticles having 
a faster rate of erosion were expected to have enhanced rate of drug release. 
The spray congealed microparticles of RIF-PEG, RIF-PEG-K100LV and RIF-
PEG-K15M were sieved (125 to 250 µm) and subjected to dissolution study. 
Figure 42 shows the dissolution profiles of RIF powder and RIF-PEG 
microparticles at pH 6.8.  
 
 
Figure 42. Dissolution profiles of RIF powder and RIF-loaded microparticles 
at pH 6.8. 



























The RIF powder dissolved very slowly as it is very poorly soluble at 
pH 6.8. Only 32.7 % of the drug dissolved after 60 min. The rate of RIF 
dissolution markedly improved when the drug was incorporated into the PEG 
microparticles (p < 0.05). The use of a hydrophilic matrix like PEG enhanced 
the drug release to 82.3 % at 60 min. Among the spray congealed 
microparticles, release of RIF increased in the following order: RIF-PEG-
K15M < RIF-PEG < RIF-PEG-K100LV. The drug release from RIF-PEG-
K15M and RIF-PEG is in good agreement with their rate of erosion. RIF-
PEG-K15M demonstrated a slower rate of erosion (1.50 to 1.62 µm
2
/s) 
compared to RIF-PEG (1.73 to 1.82 µm
2
/s). The rates of erosion reported in 
the brackets were obtained from the surface plots (Figure 41b). Drug was 
released from the microparticles by diffusion of dissolved RIF through the 
swollen HPMC layer, as well as, by erosion of the swollen layer and 
microparticle matrix. The formation of a barrier reduced the erosion rate of the 
microparticle and subsequently retarded drug release of RIF. The RIF-PEG-
K100LV microparticles showed greater improvement in drug release (85.0 % 
at 60 min) compared to the RIF-PEG microparticles. However, the erosion 
rate of K100 LV microparticles (1.63 to 2.25 µm
2
/s; obtained from Figure 
41b) was not significantly faster than that of RIF-PEG microparticles (p > 
0.05). The improvement in drug release could be due to the swellability and 
faster hydration of K100 LV in the microparticles. Hence, the grade of HPMC 
used affected drug release. Spray congealing was able to enhance the release 
of RIF significantly. By employing HPMC of the appropriate grade, the 




D. Summary for Part VI 
The swelling extent of microparticles was influenced by the grade, 
particle size and number of HPMC particles present. Rate of erosion was 
dependent on the formation of diffusion barrier and grade of HPMC used. 
Spray congealed RIF showed more rapid drug release. The grade and 
concentration of HPMC employed in the formulation could give rise to release 
enhancing or retarding effects, which could be exploited to modify the release 
of drug from PEG-based microparticles. 
 
Part VII. Effect of HPMC on MNZ crystallinity in spray congealing and 
during storage 
The different particle size of HPMC could influence the nucleation and 
crystal growth of MNZ in the spray congealing process. To study this effect, it 
is important to ensure that MNZ is fully soluble in molten PEG. The solubility 
ratio of MNZ to PEG was determined to be 1:8 at 100 °C. Therefore, the 
formulations in this study contained 10 % MNZ and at least 80 % PEG. 
HPMC K15M of various mesh sizes was added at 5 or 10 % to produce spray 
congealed microparticles (Table 14).  
 
A. Impact of HPMC particle size on MNZ crystallinity 
 The microparticles were stored at 25 °C and 30 % RH and their MNZ 
crystallinity monitored over a period of 3 months using x-ray diffractometry. 
MNZ crystallinity was indicated by the peak intensity at 12.5° (Figure 43). No 
particular trend was observed in the peak intensities of the formulations at the 
various time intervals. 
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Table 14. Formulations containing HPMC K15M of different mesh sizes and 
median particle size. 
Formulation HPMC mesh size 
(µm) 
Median HPMC particle size  
± SD (µm)* 
Control (no HPMC) - - 
A 20 – 30 33 ± 0.3 
B 40 – 50 59 ± 0.2 
C 70 – 80 114 ± 1.6 
D 100 – 120 181 ± 4.3 
E 160 – 200 275 ± 3.7 
*Median particle size determined experimentally by laser diffractometry 
 
 
Figure 43. Peak intensities in XRD spectra of various formulations monitored 
over a period of 3 months at 25 °C and 30 % RH. 
 
Further analysis was carried out by calculating the percentage 


























































corresponding physical mixture. To enable more meaningful data 












































































Figure 44. Scatter plot of drug crystallinity of various formulations.  
*Points indicate measurements at different time intervals: week 0 (black), 
week 1 (red), week 4 (green) and week 12 (blue). Horizontal bar indicates 
mean percentage reduction in drug crystallinity. 
 
Mean percentage reduction in MNZ crystallinity of freshly spray 
congealed (week 0) microparticles without HPMC (control) was 
approximately 75 %. This demonstrates that the spray congealing process was 
able to alter the solid state of the drug from crystalline to amorphous particles 
and molecular dispersion leading to a reduction in drug crystallinity. The rapid 
cooling and solidification of the molten droplets prevented the drug molecules 
from rearrangement into its crystalline form. Spray congealed microparticles 
were also stable over 3 months (week 12) when stored at 25 °C and 30 % RH 
141 
 
as the percentage reduction in drug crystallinity at different time intervals did 
not change significantly. Metronidazole largely remained in the non-
crystalline state after spray congealing.  
Generally, all formulations containing HPMC exhibited a greater 
reduction in drug crystallinity. The non-crystalline drug existed as amorphous 
particles and molecular dispersion. HPMC particles served as a nucleating site, 
allowing MNZ molecules to deposit on the surface of the particle and orientate 
in a random and haphazard manner, leading to formation of amorphous 
particles. In addition, the MNZ molecules also remained molecular dispersed 
through hydrogen bonding with HPMC and PEG. Formulations A-5% and A-
10% showed the greatest reduction in drug crystallinity (82.9 % and 81.9 % 
respectively) compared to all other formulations. It could be postulated that 
smaller HPMC particles (33 µm; Table 14) delayed nucleation and crystal 
growth of MNZ more than larger particles. At the same concentration, HPMC 
with a smaller particle size would be present in a larger number leading to a 
higher probability of the MNZ molecules adsorbing onto the surface of the 
particles. Hence, fewer crystals were formed, resulting in lower drug 
crystallinity. Larger HPMC particles of 59 µm and above decreased the 
crystallinity of MNZ to a similar extent. Therefore, there was a critical HPMC 
particle size (59 µm), where particles smaller than the critical size enhanced 
the reduction in crystallinity of MNZ. 
No significant differences in the percentage reduction in drug 
crystallinity were observed between 5 % and 10 % HPMC concentration of the 
same mesh size, leading to the inference that particle size played a greater role 
in reduction of drug crystallinity than HPMC concentration.  
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B. Summary for Part VII 
 Spray congealing was found to decrease MNZ crystallinity and the 
incorporation of HPMC reduced the crystallinity further. Particle size of 
HPMC played an important role, with smaller HPMC particles (33 µm) 
producing greater percentage reduction in MNZ crystallinity. Spray congealed 
microparticles did not show any significant change in MNZ crystallinity over 
3 months of storage at 25 °C and 30 % RH. Increasing HPMC concentration 
from 5 to 10 % had insignificant effect on MNZ crystallinity.  
 
Part VIII. Modification of drug release from spray congealed 
microparticles and the feasibility of developing the microparticles into 
tablets  
Previously, it was found that the addition of up to 10 % HPMC 
(PMH10) did not significantly modify the release of MNZ but the dissolution 
was reduced with the addition of 15 % HPMC (PMH15) into the 
microparticles. Since PMH15 had the potential to modify the release of MNZ 
from the microparticles, HPMC concentration of 15 % was selected for further 
studies with various additives. Table 15 lists the various additives employed in 
the formulation and the reasons for their selection. Two different 
concentrations of additives, low (1 %) and high (5 %), were added to the 
formulation PMH15. The concentration used was limited by the viscosity of the 






Table 15. Reasons for chosen additives. 
Additives Reasons 
Dicalcium phosphate (DCP) Insoluble in water; Reduces the hydration of 
microparticles  
Magnesium stearate (MgSt) Hydrophobic excipient; Relatively more 
hydrophobic than DCP  
Methylcellulose (MC) Hydrophilic excipient; Ability to swell and 
gel together with HPMC 
Polyvinylpyrrolidone (PVP) Hydrophilic excipient; Ability to swell, bind 
with the PEG matrix and gel together with 
HPMC 
Silicon dioxide (SiO2) Hydrophilic excipient; Increases speed of 
hydration for faster swelling of HPMC and 
barrier formation 
Sodium oleate/Citric acid Formation of a coat layer in an acidic 
environment  
 
The modulation of drug release can be achieved by (1) decreasing the 
gelation time of HPMC or (2) by providing sufficient time for HPMC to swell 
and form a barrier. The former can be achieved by increasing the speed of 
HPMC hydration by water while the latter by physically retarding the water 
from over-hydrating the microparticles, thereby preventing disintegration of 
PEG and providing more time for HPMC particles to swell and form a barrier.  
Metronidazole is known to be a drug substance with poor granulating 
and tabletting properties due to its needle-shaped crystals (Di Martino et al., 
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2007). Needle-shaped particles have poorer flow and compactibility properties 
compared to the more spherical particles (Aulton, 2007; Kaerger et al., 2004). 
Direct compression of MNZ with HPMC and PEG would pose flow and 
tabletting problems. Therefore, there is a need to incorporate MNZ into spray 
congealed microparticles before tabletting to overcome the afore-mentioned 
problems. The feasibility of developing MNZ tablets containing spray 
congealed microparticles was investigated. 
 
A. Dissolution of microparticles containing various additives 
  Figure 45 shows the various dissolution profiles of formulations 
containing various additives at a low additive concentration. Formulations 
with MgSt or sodium oleate/citric acid had the fastest drug release. The coat 
layer formed by sodium oleate in the presence of an acidic environment (citric 
acid) was unable to prolong the release of MNZ whereas the hydrophobic 
MgSt could have prevented the wetting of HPMC particles by water. Without 
the wetting and swelling of HPMC particles, no barrier could be formed. 
Formulations containing PVP K90, MC or SiO2 all showed fast drug release 
while formulation with DCP was slower than PMH15 without additives. At a 
low concentration, PVP K90 was unable to bind the HPMC particles together. 
Similar effect was seen with SiO2 and MC, in which the PEG matrix of the 
microparticles hydrated rapidly and disintegrated before the HPMC particles 
could hydrate to form a barrier. The hydrophilicity of these excipients could 
have led to greater hydration of the matrix and thus enhanced the drug release. 
On the other hand, DCP was able to prolong the release of the drug from 
microparticles. The hydration of the matrix was reduced to an appropriate 
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degree to prevent disintegration of PEG while allowing HPMC particles to 
hydrate, swell and form the barrier.  
 







PMH15 with 1% DCP
PMH15 with 1% MC
PMH15 with 1% SiO2
PMH15 with 1% PVP K90
PMH15 with 1% MgSt






















PMH15 with 1% DCP
PMH15 with 1% MC
PMH15 with 1% SiO2
PMH15 with 1% PVP K90
PMH15 with 1% MgSt
















Figure 45. Dissolution profiles of spray congealed microparticles with various 
additives at 1 % concentration: (a) as a function of time and (b) as a function 
of log time. 
 
Figure 46 shows the various dissolution profiles of formulations 
containing various additives at a high additive concentration. The addition of 
MgSt at 5 % concentration did not have the desired effect of prolonging the 
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Figure 46. Dissolution profiles of spray congealed microparticles with various 
additives at 5 % concentration: (a) as a function of time and (b) as a function 
of log time. 
Note: Formulation with 5 % PVP K90 was too viscous to spray.  
 
 
when 1 % MgSt was employed. Thus, the hydrophobicity of an additive has to 
be suitable because hydration of HPMC would decrease if the additive used is 
too hydrophobic. The addition of SiO2 at high concentration also did not 
sufficiently allow time for hydration of HPMC as the dissolution profile 
demonstrated faster release than PMH15. Both PMH15 and the formulation 





PMH15 with 1 % MC concentration showed faster dissolution than PMH15 
without any additive. Higher MC concentration, having greater gelling effect, 
would have slowed the dissolution of the microparticles. However, the fast 
hydration of the PEG matrix and the gelation effect could have nullified each 
other. Thus, the resultant effect was similar to PMH15. The addition of DCP at 
5 % sufficiently prolonged the release of the drug with 87.7 % of MNZ 
released at 60 min. The hydration of the microparticles was retarded and 
HPMC had sufficient time to swell and form a barrier.  
The modulation of drug release by decreasing the gelation time of 
HPMC using hydrophilic excipient was ineffective. A better approach to 
modulate drug release from the microparticles was to provide sufficient time 
for HPMC to swell and form a barrier. The addition of 5 % DCP successfully 
modified the release of MNZ from spray congealed microparticles containing 
HPMC. 
 
B. Screening of tablet formulations using manual tablet press 
 The purpose of screening was to ensure that the selected tablet 
formulation was suitable for further development. Two criteria have to be 
fulfilled at this stage, (1) the drug content of the tablets should be clinically 
relevant (200 mg of MNZ) and (2) the disintegration time of the tablets should 
comply with pharmacopeial specifications. The formulations compressed at 
different pressures are shown in Table 16. Microparticles containing 10 % 
MNZ and 15 % HPMC were used. The internal and external MNZ refers to 
the drug amount in the inner phase (i.e. in the microparticles) and additional 
drug added to the outer phase (i.e. outside the microparticles) respectively. 
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The external MNZ would provide a burst release of the drug upon 
disintegration of the tablet and the internal MNZ would provide a modified 
release of the drug. Lactose was used as filler to prepare tablets of 1000 mg 
each. Physiologically, the tablets should be able to disintegrate upon contact 
with the gastrointestinal fluid and release the microparticles into the 
surrounding environment to exert the therapeutic effect. 
 
Table 16. Tablet formulations screened using manual tablet press. 













F1  - - 200 800 1.0 
F2 750 75 - 250 1.0 
F3 750 75 125 125 1.0 
F4 500 50 150 350 1.0 
F5 250 25 175 575 1.0 
F6 500 50 150 350 0.5 
F7 250 25 175 575 0.5 
F8 500 50 150 350 0.25 
 
The disintegration time for the various formulations is shown in Figure 
47. Tablets of F1 (control) had very rapid disintegration. However, tablets 
containing a high amount of microparticles alone (F2) did not disintegrate 
within the pharmacopeial specification of 15 min. Therefore, further 
formulations (F3 to F5) prepared had decreased amount of microparticles and 
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external MNZ was added to constitute the final dosage strength of 200 mg. 
However, the disintegration time of these tablets was still unsatisfactory.  
F1 F2 F3 F4
 




























Figure 47. Disintegration time for tablet formulations prepared using manual 
tablet press. 
 
Tablets compressed at lower compression pressures have lower 
mechanical strength and faster disintegration time. Hence, subsequent tablets, 
F6 and F7, were prepared with the same composition as F4 and F5 
respectively, using a lower compression pressure of 0.5 tonne. Only F7 tablets 
demonstrated acceptable disintegration time. Formulation F4 was also 
compressed at a lower pressure of 0.25 tonne, but the resulting tablets, F8, had 
disintegration time exceeding the pharmacopeial specifications. Hence, only 
formulation F7 was selected for further study using the instrumented rotary 





C. Optimisation of rotary tablet press parameters  
The rotary tablet press is used by the pharmaceutical industry to mass 
manufacture tablets. Hence, investigations were performed on the rotary tablet 
press to assess the feasibility of producing tablets containing spray congealed 
microparticles. In the electrically-operated rotary tablet press, pre-determined 
compression thickness was adjusted instead of compression force. 
Compression thickness affects the compression force and the resultant tablet 
hardness. A larger compression thickness would result in lower compression 
force and tablet hardness. Tablet hardness has to be appropriate to withstand 
the mechanical stress during handling, transport or other processes besides 
being able to disintegrate. Optimisation of the compression thickness was 
carried out. Compression force and tablet hardness decreased fairly linearly (r
2 
= 0.96 and 0.99 respectively) with increase in compression thickness (Figure 
48).  
The compression thickness of 4.0 mm and below resulted in tablets 
with high hardness of more than 50 N. Suitable tablet hardness of 25 - 39 N 
was achieved with compression thickness of 4.50 mm and 4.25 mm, 
corresponding to compression force of 5 - 7 kN. A suitable hardness is 
required to ensure that the disintegration time meets the pharmacopeial 
specifications. Hence, in subsequent studies, tablets were produced using 






Figure 48. Relationship of compression thickness with compression force and 
tablet hardness. 
 
D. Production and characterisation of MNZ tablets 
 Metronidazole tablets were produced using the rotary tablet press with 
tabletting speed of 25 tablets per min with compression thickness of 4.25 mm 
and 4.50 mm (Figure 49). Based on formulation F7, tablets consisting of 
different types of microparticles were produced. The microparticles used 
consisted of PM, PMH5, PMH10, PMH15, PMH15 with 1 % DCP and PMH15 
with 5 % DCP. The thickness and hardness of the resultant tablets were 
characterised (Table 17). Using the same microparticle formulation, the tablets 
produced using a compression thickness of 4.50 mm had higher thickness but 
their hardness was lower compared to those produced using compression 
thickness of 4.25 mm. Regardless of compression thickness used, tablets with 
DCP had significantly lower tablet hardness compared to the other tablets (p < 
0.05). This suggests that DCP reduced particle-particle bonding, leading to 
lower mechanical strength upon compaction. 














































Figure 49. Metronidazole tablets containing spray congealed microparticles.  
 
Table 17. Properties of tablets composed of different microparticles. 
Compression 
thickness (mm) 





PM 5.34 ± 0.01 42 ± 3 
PMH5 5.34 ± 0.01 49 ± 1 
PMH10 5.37 ± 0.01 39 ± 1 
PMH15 5.35 ± 0.01 38 ± 1 
PMH15 with 1 % DCP  5.35 ± 0.01 31 ± 1 
PMH15 with 5 % DCP 5.35 ± 0.01 29 ± 1 
4.50 
PM 5.55 ± 0.01 29 ± 1 
PMH5 5.55 ± 0.01 33 ± 1 
PMH10 5.55 ± 0.01 24 ± 1 
PMH15 5.55 ± 0.01 25 ± 2 
PMH15 with 1 % DCP  5.58 ± 0.01 18 ± 1 
PMH15 with 5 % DCP 5.56 ± 0.01 17 ± 1 
  
From the compression and ejection profile of each tablet produced 
using the instrumented tablet press, the compression force and ejection force 














































































































































































Figure 50. (a) Compression force, (b) ejection force and (c) disintegration 




various formulations. The compression force measured was significantly 
lower for the compression thickness of 4.50 mm compared to 4.25 mm (p < 
0.05). However, within each compression thickness, the force was similar 
among the different formulations. The ejection force of all the tablet 
formulations from the two compression thickness were similar (p > 0.05) 
(Figure 50b). A high ejection force indicates sticking of the tablet to the die 
wall, which is undesirable in tablet production. Disintegration test was also 
carried out for the above tablets (Figure 50c). For the same formulation, the 
tablets produced from a compression thickness of 4.25 mm generally had 
longer disintegration time compared to those produced from a compression 
thickness of 4.50 mm. Tablets with higher hardness tend to have longer 
disintegration time. Regardless of the formulation used, all tablets produced 
from compression thickness of 4.50 mm demonstrated satisfactory 
disintegration time of less than 15 min. No direct correlation was observed 
between measured compression force and disintegration time.  
 Therefore, the production of metronidazole tablets containing spray 
congealed microparticles with satisfactory hardness and disintegration time 
could be achieved with the compression thickness of 4.50 mm, regardless of 
the formulation. The compression force of approximately 4000 N was 
determined to be optimal for production of these tablets. 
 
E. Summary for Part VIII 
 Modified drug release of spray congealed PEG-HPMC microparticles 
was successfully achieved with the addition of 5 % DCP. Other additives 
added, such as MgSt, MC, PVP, SiO2 and sodium oleate/citric acid did not 
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sufficiently modify the drug release from the microparticles. Metronidazole 
tablets containing spray congealed microparticles were developed with 
formulation comprising 25.0 % microparticles, 17.5 % external MNZ and 57.5 
% lactose. The compression thickness of 4.50 mm was optimised for the 
production of the tablets in a rotary tablet press with tabletting speed of 25 
tablets per min. Compression force of 4000 N was found to be suitable for 



























Screening of PEG as a suitable matrix showed that the PEG grade used 
has an impact on the MNZ crystallinity in solid dispersions. Lower molecular 
weight PEG resulted in lower MNZ crystallinity. Viscosity of the molten 
mixture was found to play an important role in affecting the drug crystallinity 
at low drug concentration but not at higher drug concentration. Amorphous 
and molecularly dispersed MNZ was thermodynamically stable in PEG 3350 
and showed a good percentage reduction in MNZ crystallinity. Screening of 
additives to be used in spray congealing showed that HPMC was suitable with 
regards to excipient compatibility and molten mixture viscosity.  
The influence of various grades and concentration of HPMC on the 
viscosity of binary (without drug) and ternary (with drug) PEG melt 
suspensions was determined. For all grades of HPMC, the amount of HPMC 
added to molten PEG had a greater impact than temperature in changing the 
viscosity of PEG melt suspensions. Particle size of HPMC played an important 
role in affecting the viscosity of PEG melt suspensions, with smaller particles 
resulting in higher viscosity than larger particles. This effect was more evident 
at low rather than high concentration of HPMC.  
Principal component analysis was employed to evaluate the viscosity 
of polymer melt suspensions. The ternary melt suspensions were successfully 
classified into three clusters, namely low, moderate and high according to their 
viscosities. Formulations in the low viscosity cluster were found to be 
sprayable without choking the delivery system of the spray congealer. Hence, 
PCA was suitable as a tool that enabled the evaluation and selection of an 
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appropriate grade and concentration of HPMC to achieve the desired viscosity 
for the pharmaceutical process. 
HPMC altered the properties of PEG matrix and MNZ when used as an 
additive in microparticles produced by milling of the solid dispersions. The 
addition of HPMC decreased the size of the microparticles obtained, 
indicating a decrease in mechanical strength of the matrix. The reduction in 
MNZ crystallinity was due to the presence of HPMC and not the viscosity of 
the molten mixture.  
HPMC was successfully incorporated into spray congealed PEG-MNZ 
microparticles where it exerted a significant effect on the properties of the 
drug and characteristics of the microparticles produced. Spherical and free 
flowing microparticles with good yield were obtained. An increase in HPMC 
concentration increased the viscosity of the molten mixture and size of the 
resultant microparticles, with little effect on their polydispersity. The 
microparticles produced had good encapsulation efficiency of MNZ. 
Furthermore, microparticles containing HPMC had decreased MNZ 
crystallinity, with the drug existing mostly as a molecular dispersion besides 
amorphous particles after spray congealing. Microparticles with lower HPMC 
concentration showed more rapid drug release, which was largely attributed to 
the reduction in MNZ crystallinity due to spray congealing. Higher HPMC 
concentrations resulted in slower drug release due to the formation of a 
diffusion barrier by HPMC.  
The swelling extent of microparticles was influenced by the grade, 
particle size and amount of HPMC particles present in the microparticle. Rate 
of erosion was dependant on the formation of the barrier and the grade of 
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HPMC used. The grade of HPMC employed in the formulation was able to 
further modify the release of drug, RIF, either by the enhancing or retarding 
effect.  
Particle size of HPMC played an important role in affecting MNZ 
crystallinity, with smaller particles having a greater effect in reducing the drug 
crystallinity. Spray congealed microparticles did not show any significant 
change in MNZ crystallinity over 3 months of storage at 25 °C and 30 % RH.  
Further modification of drug release of spray congealed PEG-HPMC 
microparticles was achieved with incorporation of other additives. Drug 
release of MNZ from the microparticles was retarded with the addition of 5 % 
DCP into the formulation. The spray congealed microparticles were developed 
into pharmaceutical tablets. Formulation and tabletting parameters were 
































Further studies can be carried out on the swelling effect of the 
microparticles. By using different excipients with swellability potential and 
different hydrophilic/hydrophobic drugs, the impact of swelling on the release 
of the drugs from spray congealed microparticles can be further explored. 
Additionally, the use of surface dissolution imaging method can be helpful to 
investigate the intrinsic dissolution rate of the drug as the drug dissolves and 
diffuses out of the swollen microparticles. 
The crystallinity of the drug was decreased by HPMC and the 
amorphous/molecularly dispersed form was stable during storage over 3 
months at 25 °C and 30 % RH. However, recrystallisation of the drug can be 
affected by storage at elevated temperature and humidity. The water activity, 
which is the measurement of the availability of water in a system, can lead to 
recrystallisation of drug, hydrolysis of drug and caking/clumping of powder. 
Therefore, it would be interesting to subject the spray congealed 
microparticles to various humidity levels and correlate the change in drug 
crystallinity over time with the water activity of the microparticles.  
To optimise the spray congealing process, process analytical 
technology can also be explored to monitor the production of spray congealed 
microparticles in real time. In-line particle sizer can be used to evaluate the 
microparticle size immediately after the spraying process. This allows the 
adjustment of atomising pressure and feed rate to control the size of 
microparticles produced.   
A high content of spray congealed microparticles in the tablet 
formulation could lead to the damage of the individual microparticle upon 
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compression. The drug release properties will be affected if the microparticles 
are damaged. However, this can be overcome with the use of appropriate 
diluents as cushioning agents to protect the microparticles during the 
compression process. Further investigation can be carried out to evaluate the 
suitability of different diluents so as to allow the development of tablets 
containing a higher content of microparticles. Dissolution studies on the 
tablets produced can also provide useful information in developing a drug 
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Appendix 1. Matrix materials, active principles and additives employed in 
spray congealing. 
Matrix materials Active principles Additives 
Carnauba wax Aminolevulinic acid Chitosan  
Cetostearyl alcohol Aspirin Ethylcellulose 
Glyceryl behenate Atenolol Lecithin 
Glyceryl palmitostearate Avobenzone Phosphatidylcholine 
Glycerol tripalmitate  Azithromycin dehydrate Poloxamer  
Glyceryl 
tristearate/tristearin  
Benzoic acid Polyethylene 
Hydrogenated castor oil Bovine serum albumin Polyoxyethylene 
sorbitan monooleate 
Hydrogenated palm oil  Bupivacaine Rosin 
Hydrogenated soybean 
oil  
Caffeine  Silicon dioxide 
Microcrystalline wax  Carbamazepine Sodium 
carboxymethylcellulose  
Palmitic acid Clarithromycin Sorbitan monooleate  
PEG 4000 Crystalline human 
insulin 
 
PEG 5500 Diclofenac  
PEG 6000 Econazole nitrate  
Poloxamer  Estradiol cypionate  
Polyorthoester Felodipine  




Stearyl alcohol Indomethacin  
Trimyristin Lidocaine hydrochloride  
Witepsol H15 Mesalazine  
 Piroxicam  




 Salbutamol sulphate  
 Silybum Marianum  
 Sulfamethylthiadiazole  
 Sulfathidole  








 Vitamin E  
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Appendix 2. Properties of various grades of HPMC. 






K-series    
K100M 22 8.1 100000 
K15M 22 8.1 15000 
K4M 22 8.1 4000 
K100 LV 22 8.1 100 
E-series    
E4M 29 8.5 4000 
E50 LV 29 8.5 50 
E15 LV 29 8.5 15 
F-series    
F4M 28 5.0 4000 
F50 LV 28 5.0 50 
Special series    
Methocel vLV - - < 2 
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